MCID: VGN017
MIFTS: 63

Vaginal Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Vaginal Cancer

MalaCards integrated aliases for Vaginal Cancer:

Name: Vaginal Cancer 11 19 41 14 75 33
Malignant Neoplasm of Vagina 11 31
Vaginal Neoplasms 43 71
Primary Malignant Neoplasm of Vagina 33
Vaginal Malignant Epithelial Tumor 58
Malignant Vaginal Neoplasm 71
Malignant Tumour of Vagina 33
Malignant Tumor of Vagina 11
Malignant Vaginal Tumor 11
Carcinoma of Vagina 33
Vaginal Wall Cancer 33
Neoplasm of Vagina 11
Vagina Wall Cancer 33
Vaginal Carcinoma 58
Vaginal Neoplasia 71
Vaginal Neoplasm 16
Vagina Carcinoma 71
Cancer of Vagina 33
Vagina Neoplasm 11
Vaginal Tumor 11

Characteristics:


Age Of Onset:

Vaginal Carcinoma: Adult,Elderly 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:119
ICD9CM 34 184.0
MeSH 43 D014625
NCIt 49 C3437 C7410
SNOMED-CT 68 126921000 188210000
ICD10 31 C52
ICD10 via Orphanet 32 C52
UMLS via Orphanet 72 C0262659
Orphanet 58 ORPHA180247
UMLS 71 C0042237 C0042258 C0262659 more

Summaries for Vaginal Cancer

MedlinePlus: 41 Vaginal cancer is a rare type of cancer. It is more common in women 60 and older. You are also more likely to get it if you have had a human papillomavirus (HPV) infection or if your mother took diethylstilbestrol (DES) when she was pregnant. Doctors prescribed DES in the 1950's to prevent miscarriages. You are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. It often doesn't have early symptoms. However, see your doctor if you notice: Bleeding that is not your period A vaginal lump Pelvic pain A Pap test can find abnormal cells that may be cancer. Vaginal cancer can often be cured in its early stages. Treatment might include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary: Vaginal Cancer, also known as malignant neoplasm of vagina, is related to vaginal endometrial stromal tumor and vagina sarcoma, and has symptoms including pelvic pain and vaginal pruritus. An important gene associated with Vaginal Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and ERK Signaling. The drugs Octreotide and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include vagina, cervix and uterus, and related phenotypes are homeostasis/metabolism and nervous system

Orphanet: 58 A group of rare vaginal tumors comprising HPV-associated and HPV-independent squamous cell carcinoma, glandular tumors (including HPV-associated adenocarcinoma, endometrioid carcinoma, clear cell carcinoma, gastric type and intestinal type mucinous carcinoma, and mesonephric adenocarcinoma), adenocarcinoma of Skene gland origin, adenosquamous carcinoma, and adenoid basal carcinoma. Depending on the type of tumor and disease stage, patients may present with symptoms related to a vaginal mass, vaginal bleeding and/or discharge, postcoital bleeding, urinary symptoms, pelvic pain, and a foreign body sensation within the vagina.

Disease Ontology: 11 A female reproductive system cancer that is located in the vagina.

Wikipedia: 75 Vaginal cancer is an extraordinarily rare form of cancer that develops in the tissue of the vagina.... more...

Related Diseases for Vaginal Cancer

Diseases related to Vaginal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 627, show less)
# Related Disease Score Top Affiliating Genes
1 vaginal endometrial stromal tumor 31.7 MME CALD1
2 vagina sarcoma 31.4 PGR MME ESR1 CALD1
3 vaginal disease 31.4 MAPK8IP1 ESR1 CD8A CD4
4 vaginal carcinosarcoma 31.0 TP53 MME KRT7 HRAS
5 suppressor of tumorigenicity 3 30.1 UBE3A TP53 CDKN2A
6 vulval paget's disease 30.0 KRT7 CDKN2A
7 mesenchymal cell neoplasm 30.0 TP53 MME CALD1
8 endometriosis 29.9 TP53 PTEN PGR ESR1
9 mammary paget's disease 29.9 PGR KRT7 ESR1
10 clear cell adenocarcinoma 29.7 TP53 MME KRT7
11 vaginal discharge 29.7 PGR MAPK8IP1 KRT7 ESR1 CD4
12 leiomyosarcoma 29.7 TP53 PGR ESR1 CDKN2A CD274 BRCA1
13 human papillomavirus infectious disease 29.6 TP53 PTEN HRAS GP5 EGFR CDKN2A
14 adult t-cell leukemia/lymphoma 29.6 TP53 CD8A CD4
15 endometrial hyperplasia 29.5 TP53 PTEN PGR ESR1 CDKN2A
16 cervix uteri carcinoma in situ 29.5 TP53 MAPK8IP1 INSM1 GP5 CDKN2A CD4
17 neuroendocrine carcinoma 29.5 PTEN PGR KRT7 ESR1
18 severe cutaneous adverse reaction 29.5 CD8A CD4 CD274
19 cervical squamous cell carcinoma 29.5 TP53 PTEN EGFR CDKN2A
20 rectal benign neoplasm 29.4 TP53 KRT7 HRAS EGFR
21 cervical cancer 29.4 UBE3A TP53 PTEN HRAS CDKN2A
22 squamous cell carcinoma 29.3 TP53 PTEN KRT7 HRAS EGFR CDKN2A
23 adenosquamous carcinoma 29.2 PGR MAPK8IP1 KRT7 INSM1 HRAS EGFR
24 anogenital venereal wart 29.2 UBE3A TP53 GP5 CDKN2A CD8A CD4
25 myoma 29.1 TP53 PGR MME ESR1 EGFR CALD1
26 keratinizing squamous cell carcinoma 29.0 TP53 KRT7 HRAS EGFR CDKN2A
27 vulva cancer 29.0 TP53 PTEN KRT7 HRAS GP5 EGFR
28 breast ductal carcinoma 29.0 TP53 PTEN PGR KRT7 ESR1 EGFR
29 vulva squamous cell carcinoma 29.0 TP53 HRAS GP5 EGFR CDKN2A CD274
30 papilloma 28.9 UBE3A TP53 PTEN KRT7 ESR1 EGFR
31 squamous cell carcinoma, head and neck 28.8 TP53 PTEN HRAS EGFR CDKN2A
32 adenocarcinoma 28.8 TP53 PTEN KRT7 HRAS EGFR CDKN2A
33 adenocarcinoma in situ 28.5 TP53 MAPK8IP1 KRT7 INSM1 HRAS GP5
34 in situ carcinoma 28.3 TP53 PTEN PGR KRT7 INSM1 HRAS
35 vulvar disease 28.3 TP53 PTEN KRT7 HRAS GP5 EGFR
36 endometrial cancer 28.0 TP53 PTEN PGR MME KRT7 HRAS
37 anus cancer 27.9 UBE3A TP53 KRT7 HRAS GP5 EGFR
38 connective tissue disease 27.8 TP53 PTEN HRAS ESR1 EGFR CDKN2A
39 rhabdomyosarcoma 27.7 TP53 PTEN MME KRT7 HRAS ESR1
40 leukemia, acute myeloid 27.1 TP53 PTEN MME HRAS ESR1 EGFR
41 cervix carcinoma 26.8 TP53 PTEN PGR MAPK8IP1 KRT7 INSM1
42 vaginal glandular tumor 11.0
43 vaginal squamous tumor 11.0
44 vaginal yolk sac tumor 11.0
45 diethylstilbestrol syndrome 11.0
46 early invasive cervical adenocarcinoma 10.4 INSM1 CDKN2A
47 adenosquamous breast carcinoma 10.4 TP53 PGR
48 nipple carcinoma 10.4 PGR ESR1
49 breast mucinous cystadenocarcinoma 10.4 PGR ESR1
50 breast fibroadenosis 10.4 PGR ESR1
51 middle ear squamous cell carcinoma 10.4 GP5 CDKN2A
52 bulbospinal polio 10.4 PGR ESR1
53 spinal polio 10.4 PGR ESR1
54 penis basal cell carcinoma 10.4 GP5 CDKN2A
55 glycogen-rich clear cell breast carcinoma 10.4 PGR ESR1
56 adult cystic nephroma 10.4 PGR ESR1
57 breast cystic hypersecretory carcinoma 10.3 PGR ESR1
58 hemometra 10.3 MAPK8IP1 INSM1
59 breast squamous cell carcinoma 10.3 PGR ESR1
60 progesterone resistance 10.3 PGR ESR1
61 isthmus cancer 10.3 MAPK8IP1 INSM1
62 micropapillomatosis labialis 10.3 ESR1 CD4
63 vulvar squamous papilloma 10.3 ESR1 CD4
64 bartholin's gland adenoma 10.3 TP53 PGR ESR1
65 bartholin's gland benign neoplasm 10.3 TP53 PGR ESR1
66 vestibular gland benign neoplasm 10.3 TP53 PGR ESR1
67 pulmonary vein leiomyosarcoma 10.3 PGR CALD1
68 male reproductive organ benign neoplasm 10.3 TP53 GP5 CDKN2A
69 cervical basaloid squamous cell carcinoma 10.3 KRT7 CDKN2A
70 phimosis 10.3 TP53 GP5 CDKN2A
71 cancerophobia 10.3 MAPK8IP1 BRCA1
72 lung leiomyoma 10.3 PGR CALD1
73 nosophobia 10.3 MAPK8IP1 BRCA1
74 ovarian melanoma 10.3 MAPK8IP1 CALD1
75 inverted transitional papilloma 10.3 KRT7 CDKN2A
76 pancreatic foamy gland adenocarcinoma 10.3 TP53 KRT7
77 anal canal paget's disease 10.3 KRT7 CDKN2A
78 tonsillar pillar cancer 10.3 EGFR CDKN2A
79 endometrial transitional cell carcinoma 10.3 KRT7 CDKN2A
80 psammomatous meningioma 10.3 PGR OGN
81 vulvar leiomyosarcoma 10.3 ESR1 CALD1
82 vulvar sebaceous carcinoma 10.3 TP53 KRT7
83 ovarian mesodermal adenosarcoma 10.3 KRT7 ESR1
84 microinvasive cervical squamous cell carcinoma 10.3 KRT7 INSM1
85 necrotizing sialometaplasia 10.3 TP53 KRT7
86 urethral villous adenoma 10.3 PGR KRT7
87 vulvar syringoma 10.3 PGR ESR1
88 breast hemangioma 10.3 TP53 KRT7
89 liver leiomyoma 10.2 PGR ESR1
90 high-grade astrocytoma 10.2 TP53 PTEN
91 vagina leiomyoma 10.2 PGR CDKN2A CALD1
92 intravascular fasciitis 10.2 ESR1 CDKN2A CALD1
93 ovarian cyst 10.2 PGR ESR1 BRCA1
94 basaloid lung carcinoma 10.2 TP53 PGR BRCA1
95 well-differentiated liposarcoma 10.2 TP53 CDKN2A CALD1
96 vulvar seborrheic keratosis 10.2 PTEN CDKN2A
97 conjunctival squamous cell carcinoma 10.2 TP53 CDKN2A CD4
98 vagina leiomyosarcoma 10.2 PGR ESR1 CALD1
99 vulvar benign neoplasm 10.2 PGR ESR1 CALD1
100 diffuse peritoneal leiomyomatosis 10.2 PGR ESR1 CALD1
101 peritoneal benign neoplasm 10.2 PGR ESR1 CALD1
102 lipid-rich carcinoma 10.2 PGR ESR1
103 ovarian serous adenofibroma 10.2 TP53 PGR BRCA1
104 cervix erosion 10.2 MME MAPK8IP1
105 cervical adenomyoma 10.2 PGR MME
106 cervical benign neoplasm 10.2 PGR MME
107 male urethral cancer 10.2 TP53 KRT7 CDKN2A
108 mucinous adenofibroma 10.2 KRT7 ESR1
109 common wart 10.2 TP53 GP5 CD4
110 breast duct papilloma 10.2 PTEN PGR
111 chronic cervicitis 10.2 TP53 INSM1 GP5 CDKN2A
112 desmoid tumor 10.2 TP53 ESR1 CALD1
113 malignant spiradenoma 10.2 TP53 KRT7 ESR1
114 intratubular embryonal carcinoma 10.2 TP53 KRT7
115 frontal lobe neoplasm 10.2 TP53 EGFR
116 atrophic vulva 10.2 KRT7 ESR1 CDKN2A
117 gallbladder carcinoma in situ 10.2 TP53 MME
118 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 10.2
119 sublingual gland adenoid cystic carcinoma 10.2 PGR KRT7
120 sebaceous adenocarcinoma 10.2 TP53 KRT7 CDKN2A
121 keratosis, seborrheic 10.2 TP53 KRT7 CDKN2A
122 urinary bladder small cell neuroendocrine carcinoma 10.2 KRT7 INSM1
123 esophagus verrucous carcinoma 10.2 TP53 EGFR CDKN2A
124 fibroma 10.2 PGR KRT7 ESR1
125 penile benign neoplasm 10.2 TP53 GP5 CDKN2A CD274
126 cervical serous adenocarcinoma 10.2 PGR MME
127 comedo carcinoma 10.2 TP53 PGR GP5 ESR1
128 malignant germ cell tumor of the vagina 10.2
129 vulvovaginal rhabdomyosarcoma 10.2
130 oncocytic breast carcinoma 10.2 PGR KRT7 ESR1
131 breast papillary carcinoma 10.2 PGR KRT7 ESR1
132 laryngeal benign neoplasm 10.2 TP53 EGFR CDKN2A
133 breast adenoid cystic carcinoma 10.2 PGR KRT7 ESR1
134 gastric diffuse adenocarcinoma 10.2 PGR KRT7 ESR1
135 mixed endometrial stromal and smooth muscle tumor 10.2 MME CALD1
136 apocrine sweat gland neoplasm 10.2 PGR KRT7 ESR1
137 fallopian tube leiomyoma 10.2 MME CALD1
138 urethra leiomyoma 10.2 MME CALD1
139 intraductal papilloma 10.2 PGR KRT7 ESR1
140 urethra transitional cell carcinoma 10.2 TP53 EGFR
141 esophagus adenocarcinoma 10.2 TP53 EGFR CDKN2A
142 fallopian tube benign neoplasm 10.2 MME CALD1
143 gastroesophageal junction adenocarcinoma 10.2 TP53 EGFR CD274
144 cervix endometriosis 10.2 MME MAPK8IP1 CDKN2A
145 external ear carcinoma 10.2 UBE3A PGR KRT7
146 sex cord-gonadal stromal tumor 10.2 PGR KRT7 ESR1
147 basosquamous carcinoma 10.1 TP53 KRT7
148 cervical carcinosarcoma 10.1 MME MAPK8IP1 GP5
149 inflammatory breast carcinoma 10.1 PGR ESR1 EGFR
150 uterine sarcoma 10.1 MME ESR1
151 cholecystitis 10.1 TP53 EGFR CDKN2A
152 vaginal benign neoplasm 10.1 KRT7 CDKN2A CALD1
153 fallopian tube endometrioid adenocarcinoma 10.1 MME INSM1 CDKN2A
154 cervical intraepithelial neoplasia 10.1
155 breast leiomyosarcoma 10.1 KRT7 ESR1 CALD1
156 myxofibrosarcoma 10.1 TP53 CDKN2A CD274 CALD1
157 uterine corpus adenosarcoma 10.1 PGR MME ESR1
158 dedifferentiated liposarcoma 10.1 TP53 CDKN2A CD274 CALD1
159 sclerosing hemangioma 10.1 TP53 PTEN PGR
160 epithelial-myoepithelial carcinoma 10.1
161 mixed oligodendroglioma-astrocytoma 10.1 TP53 PTEN CD274
162 adult type testicular granulosa cell tumor 10.1 PGR MME
163 atypical polypoid adenomyoma 10.1 MME CALD1
164 bartholin's gland disease 10.1 PGR KRT7 CALD1
165 spindle cell sarcoma 10.1 TP53 KRT7 CALD1
166 benign breast phyllodes tumor 10.1 PGR MME ESR1
167 basaloid squamous cell carcinoma 10.1 TP53 KRT7 INSM1 CDKN2A
168 paranasal sinus cancer 10.1 TP53 KRT7 INSM1 CDKN2A
169 atypical teratoid rhabdoid tumor 10.1 TP53 EGFR CDKN2A
170 estrogen excess 10.1 PTEN PGR ESR1
171 cervical clear cell adenocarcinoma 10.1 MAPK8IP1 KRT7 GP5 CDKN2A
172 endometrial squamous cell carcinoma 10.1 TP53 PGR KRT7 CDKN2A
173 adenomyosis 10.1 TP53 PTEN ESR1
174 vascular cancer 10.1 TP53 KRT7 CALD1
175 heart leiomyosarcoma 10.1 EGFR CALD1
176 cervical mucinous adenocarcinoma 10.1 PGR MAPK8IP1 KRT7 CDKN2A
177 nephrogenic adenoma of urinary bladder 10.1 MME KRT7
178 nephrogenic adenoma 10.1 MME KRT7
179 hilar lung neoplasm 10.1 CD8A CD4
180 endometriosis of ovary 10.1 PTEN PGR ESR1
181 peritoneal mesothelioma 10.1 TP53 KRT7 CDKN2A CD274
182 breast mucinous carcinoma 10.1 PGR KRT7
183 wolffian duct adenoma 10.1 MME KRT7
184 ovarian seromucinous carcinoma 10.1 PGR KRT7 ESR1 CDKN2A
185 sweat gland disease 10.1 TP53 PGR KRT7 ESR1
186 ureteral benign neoplasm 10.1 TP53 KRT7
187 breast myofibroblastoma 10.1 MME ESR1 CALD1
188 verrucous carcinoma 10.1 TP53 GP5 EGFR CDKN2A
189 epididymal neoplasm 10.1 MME KRT7
190 oral tuberculosis 10.1 CD8A CD4
191 breast leiomyoma 10.1 PGR MME CALD1
192 early yaws 10.1 CD8A CD4
193 testicular cancer 10.1 TP53 ESR1 CD274 BRCA1
194 cutaneous leiomyosarcoma 10.1 MME CALD1
195 bone squamous cell carcinoma 10.1 TP53 EGFR CDKN2A CD274
196 glottis squamous cell carcinoma 10.1 PTEN EGFR
197 trachea carcinoma in situ 10.1 HRAS CDKN2A
198 endometrial serous adenocarcinoma 10.1 TP53 PTEN BRCA1
199 cellular leiomyoma 10.1 PGR MME CALD1
200 hypopharynx cancer 10.1 TP53 EGFR CDKN2A CD274
201 vaginal endometrial stromal sarcoma 10.1 PGR MME CALD1
202 connective tissue benign neoplasm 10.1 TP53 MME CALD1
203 ventilation pneumonitis 10.1 CD8A CD4
204 adenofibroma 10.1 TP53 MME KRT7
205 mixed epithelial stromal tumour 10.1 MME KRT7
206 lipomatosis, multiple 10.1 TP53 PTEN CALD1
207 sebaceous gland disease 10.1 INSM1 EGFR CD4
208 diffuse infiltrative lymphocytosis syndrome 10.1 CD8A CD4
209 wissler-fanconi syndrome 10.1 CD8A CD4
210 xanthogranulomatous pyelonephritis 10.1 MME KRT7
211 autoimmune lymphoproliferative syndrome, type iia 10.1 CD8A CD4
212 amelogenesis imperfecta, type ig 10.1 TP53 PGR ESR1 EGFR
213 amelogenesis imperfecta 10.1 TP53 PGR ESR1 EGFR
214 diffuse gastric cancer 10.1 TP53 PTEN BRCA1
215 pelvic organ prolapse 10.1
216 diffuse gastric and lobular breast cancer syndrome 10.1 TP53 PTEN BRCA1
217 glandular cystitis 10.1 TP53 MME KRT7
218 ethmoid sinus cancer 10.1 INSM1 HRAS
219 female urethral cancer 10.0 MME KRT7 CDKN2A
220 encephalitozoonosis 10.0 CD8A CD4
221 leiomyoma 10.0 TP53 PGR MME ESR1
222 bizarre leiomyoma 10.0 TP53 PGR ESR1 CDKN2A CALD1
223 intrahepatic bile duct adenoma 10.0 TP53 MME KRT7
224 type 1 diabetes mellitus 23 10.0 CD8A CD4
225 breast sarcoma 10.0 TP53 PGR MME ESR1
226 angelman syndrome 10.0 UBE3A TP53 PGR ESR1 CDKN2A
227 sigmoid disease 10.0 MME MAPK8IP1
228 cork-handlers' disease 10.0 CD8A CD4
229 ovarian serous cystadenofibroma 10.0 TP53 PGR KRT7 BRCA1
230 chromophil adenoma of the kidney 10.0 MME KRT7
231 liposarcoma 10.0 TP53 PTEN CDKN2A CD274
232 thymic carcinoma 10.0 KRT7 EGFR CD274
233 central nervous system hematologic cancer 10.0 MME CD4 CD274
234 follicular mucinosis 10.0 CD8A CD4
235 central nervous system lymphoma 10.0 MME CD4 CD274
236 breast adenomyoepithelioma 10.0 KRT7 HRAS
237 larynx squamous papilloma 10.0 TP53 HRAS CDKN2A
238 t-cell adult acute lymphocytic leukemia 10.0 TP53 CD8A CD4
239 breast abscess 10.0 PGR CD4
240 lichen disease 10.0 TP53 CD8A CD4
241 nephrogenic adenoma of the urethra 10.0 MME KRT7
242 t-cell prolymphocytic leukemia 10.0 TP53 CD8A CD4
243 conjunctival cancer 10.0 TP53 HRAS CDKN2A
244 suppurative lymphadenitis 10.0 CD8A CD4
245 sweat gland cancer 10.0 TP53 PGR KRT7 INSM1 ESR1
246 tatton-brown-rahman syndrome 10.0
247 cystitis 10.0
248 vaginitis 10.0
249 proctitis 10.0
250 rare tumor 10.0
251 subareolar duct papillomatosis 10.0 MME KRT7 CALD1
252 familial retinoblastoma 10.0 TP53 PTEN CDKN2A BRCA1
253 nipple benign neoplasm 10.0 MME KRT7 CALD1
254 lymphangitis 10.0 KRT7 EGFR CD4
255 granulomatous hepatitis 10.0 CD8A CD4 CD274
256 uterus perivascular epithelioid cell tumor 10.0 MME KRT7 CALD1
257 acute interstitial pneumonia 10.0 CD8A CD4 CD274
258 clear cell hidradenoma 10.0 MME KRT7
259 bird fancier's lung 10.0 CD8A CD4
260 blood protein disease 10.0 TP53 CD8A CD4
261 salivary gland carcinoma 10.0 TP53 KRT7 EGFR CDKN2A
262 cryptogenic organizing pneumonia 10.0 CD8A CD4 CD274
263 thrombocytopenia due to platelet alloimmunization 10.0 GP5 CD8A CD4
264 intravenous leiomyomatosis 10.0 PGR MME ESR1 CALD1
265 malignant peripheral nerve sheath tumor 10.0 TP53 KRT7 EGFR CDKN2A
266 autoimmune myocarditis 10.0 CD8A CD4 CD274
267 vulvar leiomyoma 10.0 PGR MME ESR1 CALD1
268 parapsoriasis 10.0 CD8A CD4
269 endometrial stromal tumor 10.0 PGR MME ESR1 CALD1
270 kidney cancer 10.0 TP53 EGFR CDKN2A CD274
271 bladder clear cell adenocarcinoma 10.0 TP53 MME KRT7 CDKN2A
272 pericardium disease 10.0 CD8A CD4 CD274
273 smooth muscle tumor 10.0 PGR MME ESR1 CALD1
274 cribriform carcinoma 10.0 PGR KRT7 ESR1 EGFR
275 peutz-jeghers syndrome 10.0 TP53 PTEN EGFR
276 nasal cavity adenocarcinoma 10.0 KRT7 HRAS
277 dysgerminoma 9.9 PTEN KRT7 BRCA1
278 idh-wildtype glioblastoma 9.9 TP53 PTEN EGFR CDKN2A
279 mixed glioma 9.9 TP53 PTEN EGFR CDKN2A
280 neurofibroma 9.9 TP53 PTEN EGFR CDKN2A
281 diffuse astrocytoma 9.9 TP53 PTEN EGFR CDKN2A
282 uterus carcinoma in situ 9.9 TP53 MAPK8IP1 INSM1 GP5 CDKN2A CD4
283 bladder urachal carcinoma 9.9 KRT7 HRAS
284 infiltrating angiolipoma 9.9 HRAS CDKN2A CALD1
285 ovarian carcinosarcoma 9.9 TP53 HRAS BRCA1
286 anaplastic oligodendroglioma 9.9 TP53 PTEN EGFR CDKN2A
287 primary syphilis 9.9 CD8A CD4
288 urachus cancer 9.9 KRT7 HRAS
289 pancreatic mucinous cystadenoma 9.9 PGR HRAS
290 ocular melanoma 9.9 HRAS CDKN2A CD274
291 extrinsic cardiomyopathy 9.9 CD8A CD4 CD274
292 inflammatory myofibroblastic tumor 9.9 TP53 KRT7 EGFR CALD1
293 hepatoblastoma 9.9 TP53 KRT7 EGFR CDKN2A
294 low grade glioma 9.9 TP53 PTEN EGFR CDKN2A
295 central nervous system benign neoplasm 9.9 TP53 PTEN EGFR CDKN2A
296 infratentorial cancer 9.9 TP53 PTEN EGFR CDKN2A
297 tubular adenocarcinoma 9.9 PGR MME KRT7 ESR1
298 vitiligo-associated multiple autoimmune disease susceptibility 1 9.9 CD8A CD4 CD274
299 breast myoepithelial neoplasm 9.9 KRT7 HRAS
300 tongue disease 9.9 TP53 PTEN EGFR CDKN2A
301 anaplastic astrocytoma 9.9 TP53 PTEN EGFR CDKN2A
302 granulomatous angiitis 9.9 CD8A CD4
303 cervicitis 9.9 GP5 CDKN2A CD8A CD4
304 rectum cancer 9.9
305 hydronephrosis 9.9
306 melanoma 9.9
307 idiopathic interstitial pneumonia 9.9
308 vulvar intraepithelial neoplasia 9.9
309 retinitis pigmentosa 11 9.9 TP53 PTEN EGFR CDKN2A
310 ovarian serous carcinoma 9.9 TP53 HRAS BRCA1
311 estrogen-receptor negative breast cancer 9.9 TP53 PGR ESR1 EGFR BRCA1
312 bladder transitional cell papilloma 9.9 TP53 KRT7 HRAS
313 appendix adenocarcinoma 9.9 TP53 KRT7 HRAS
314 biliary tract benign neoplasm 9.9 TP53 KRT7 HRAS
315 small intestine adenocarcinoma 9.9 TP53 KRT7 HRAS
316 papillary adenoma 9.9 TP53 KRT7 HRAS
317 balloon cell malignant melanoma 9.9 MME KRT7
318 appendix disease 9.9 TP53 KRT7 HRAS
319 urinary tract papillary transitional cell benign neoplasm 9.9 TP53 KRT7 HRAS
320 bladder papillary transitional cell neoplasm 9.9 TP53 KRT7 HRAS
321 clear cell basal cell carcinoma 9.9 TP53 KRT7 HRAS
322 papillary squamous carcinoma 9.9 MAPK8IP1 KRT7 INSM1 EGFR CDKN2A
323 appendix cancer 9.9 TP53 KRT7 HRAS
324 intestinal perforation 9.9 KRT7 CD8A CD4
325 gallbladder adenocarcinoma 9.9 TP53 KRT7 HRAS
326 keratoacanthoma 9.9
327 embryonal carcinoma 9.9
328 klatskin's tumor 9.9 TP53 KRT7 HRAS
329 villous adenoma 9.9 TP53 KRT7 HRAS
330 adenosquamous lung carcinoma 9.9 HRAS EGFR
331 adenosarcoma 9.9 TP53 PGR MME ESR1 CALD1
332 malignant spindle cell melanoma 9.9 TP53 HRAS CDKN2A CD274
333 duodenum cancer 9.9 TP53 KRT7 HRAS
334 duodenum disease 9.9 TP53 KRT7 HRAS
335 skeletal muscle cancer 9.9 TP53 HRAS CALD1
336 mucinous intrahepatic cholangiocarcinoma 9.9 KRT7 HRAS
337 signet ring cell adenocarcinoma 9.9 TP53 KRT7 HRAS
338 thyroid gland disease 9.9 TP53 CD8A CD4 CD274
339 fallopian tube carcinoma 9.9 TP53 PTEN KRT7 BRCA1
340 sezary's disease 9.9 TP53 CD8A CD4 CD274
341 cervical polyp 9.9 PGR MME MAPK8IP1 ESR1 CALD1
342 laryngeal squamous cell carcinoma 9.9 TP53 PTEN EGFR CDKN2A
343 endometrial stromal sarcoma 9.9 TP53 PGR MME ESR1 CALD1
344 apocrine adenocarcinoma 9.9 TP53 PGR KRT7 ESR1 EGFR
345 human cytomegalovirus infection 9.9 EGFR CD8A CD4
346 sporadic breast cancer 9.9 TP53 PTEN PGR ESR1 BRCA1
347 sigmoid neoplasm 9.9 KRT7 HRAS
348 appendiceal neoplasm 9.9 KRT7 HRAS
349 nail disease 9.9 EGFR CD8A CD4
350 colon adenoma 9.9 TP53 HRAS EGFR
351 fallopian tube disease 9.9 TP53 CD8A CD4 BRCA1
352 invasive malignant thymoma 9.8 MME CD8A CD4
353 teratoma 9.8 TP53 PTEN KRT7 ESR1 CDKN2A
354 skin benign neoplasm 9.8 TP53 KRT7 HRAS
355 primary cutaneous gamma-delta t-cell lymphoma 9.8 CD8A CD4
356 breast metaplastic carcinoma 9.8 TP53 PGR MME KRT7 ESR1
357 intraductal breast benign neoplasm 9.8 TP53 PGR MME KRT7 ESR1
358 endometrioid ovary carcinoma 9.8 TP53 PTEN HRAS
359 adult acute lymphocytic leukemia 9.8 MME CD8A CD4
360 pancreatoblastoma 9.8 MME HRAS CDKN2A
361 small cell carcinoma 9.8 TP53 PTEN KRT7 EGFR
362 angiomyolipoma 9.8 TP53 PGR MME KRT7 ESR1
363 ovarian disease 9.8 TP53 PTEN PGR ESR1 BRCA1
364 angioimmunoblastic t-cell lymphoma 9.8 MME CD8A CD4
365 colorectal adenoma 9.8 TP53 HRAS EGFR
366 plasma protein metabolism disease 9.8 MME CD8A CD4
367 hair disease 9.8 EGFR CD8A CD4
368 benign breast adenomyoepithelioma 9.8 MME KRT7 ESR1 EGFR
369 splenic disease 9.8 MME CD8A CD4
370 adenoma 9.8 TP53 KRT7 HRAS CDKN2A
371 breast malignant phyllodes tumor 9.8 TP53 PGR MME ESR1 EGFR
372 testicular germ cell tumor 9.8
373 endodermal sinus tumor 9.8
374 embryonal rhabdomyosarcoma 9.8
375 testicular yolk sac tumor 9.8
376 female breast cancer 9.8 TP53 PGR ESR1 EGFR CDKN2A BRCA1
377 cervical adenocarcinoma 9.8 TP53 PGR MAPK8IP1 KRT7 INSM1 ESR1
378 acneiform dermatitis 9.8 HRAS EGFR
379 keratosis 9.8 TP53 HRAS EGFR CDKN2A
380 transitional cell carcinoma 9.8 TP53 PTEN KRT7 EGFR
381 adult malignant schwannoma 9.8 TP53 HRAS EGFR CDKN2A
382 oligodendroglioma 9.8 TP53 PTEN LRIG2 EGFR CDKN2A
383 sweat gland benign neoplasm 9.8 TP53 PGR MME KRT7 CALD1
384 plexiform neurofibroma 9.8 TP53 HRAS EGFR CDKN2A
385 cystadenocarcinoma 9.8 TP53 PTEN PGR KRT7 BRCA1
386 lip and oral cavity cancer 9.8 TP53 HRAS EGFR CDKN2A
387 blood platelet disease 9.8 TP53 GP5 CD8A CD4 CD274
388 penile disease 9.8 TP53 GP5 EGFR CDKN2A CD4 CD274
389 bilateral breast cancer 9.8 TP53 PTEN PGR ESR1 CDKN2A BRCA1
390 tonsil cancer 9.8 TP53 PGR KRT7 ESR1 EGFR CDKN2A
391 coloboma of optic nerve 9.8
392 myositis 9.8
393 lymphoma, hodgkin, classic 9.8
394 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
395 vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome 9.8
396 polymyositis 9.8
397 dermatomyositis 9.8
398 gender incongruence 9.8
399 congestive heart failure 9.8
400 spondylitis 9.8
401 decubitus ulcer 9.8
402 polyarteritis nodosa 9.8
403 acute myeloid leukemia with recurrent genetic anomaly 9.8
404 pleural cancer 9.8 TP53 EGFR CDKN2A CD8A CD274
405 neutrophilia, hereditary 9.8
406 histiocytic sarcoma 9.8
407 midline cystocele 9.8
408 fibrosarcoma of bone 9.8
409 histiocytosis 9.8
410 choriocarcinoma 9.8
411 malignant mesenchymoma 9.8
412 ileus 9.8
413 myeloid leukemia 9.8
414 soft tissue sarcoma 9.8
415 inherited cancer-predisposing syndrome 9.8 TP53 PTEN EGFR CDKN2A BRCA1
416 bap1 tumor predisposition syndrome 9.8 TP53 PTEN EGFR CDKN2A BRCA1
417 parkinson disease, late-onset 9.8
418 porphyria cutanea tarda 9.8
419 thrombophilia due to thrombin defect 9.8
420 duodenal atresia 9.8
421 factor vii deficiency 9.8
422 chylomicron retention disease 9.8
423 neurodegeneration with brain iron accumulation 2a 9.8
424 mayer-rokitansky-kuster-hauser syndrome 9.8
425 spastic paraplegia, ataxia, and mental retardation 9.8
426 myelodysplastic syndrome 9.8
427 graft-versus-host disease 9.8
428 sexual health disorder 9.8
429 thrombosis 9.8
430 sarcoma 9.8
431 disseminated intravascular coagulation 9.8
432 porphyria 9.8
433 cholestasis 9.8
434 obstructive jaundice 9.8
435 adhesions of uterus 9.8
436 polyneuropathy 9.8
437 thrombocytopenia 9.8
438 calcinosis 9.8
439 malignant skin fibrous histiocytoma 9.8
440 leukorrhea 9.8
441 t-cell acute lymphoblastic leukemia 9.8
442 crohn's disease 9.8
443 49, xxxxy syndrome 9.8
444 49,xxxxx syndrome 9.8
445 chronic graft versus host disease 9.8
446 leukemia, t-cell, chronic 9.8
447 undifferentiated connective tissue disease 9.8
448 familial ovarian cancer 9.8
449 malignancy diagnosed during pregnancy 9.8
450 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.8
451 49,xyyyy syndrome 9.8
452 nodular malignant melanoma 9.8 TP53 PTEN HRAS CDKN2A
453 neurofibromatosis 9.7 TP53 PTEN HRAS CDKN2A
454 malignant exocrine pancreas neoplasm 9.7 TP53 HRAS EGFR CDKN2A
455 melanoma in congenital melanocytic nevus 9.7 TP53 PTEN HRAS CDKN2A
456 peripheral t-cell lymphoma 9.7 TP53 MME CD8A CD4
457 ovarian benign neoplasm 9.7 TP53 KRT7 HRAS BRCA1
458 papillary adenocarcinoma 9.7 TP53 KRT7 HRAS BRCA1
459 nasopharyngeal carcinoma 9.7 TP53 PTEN EGFR CDKN2A CD274
460 borst-jadassohn intraepidermal carcinoma 9.7 TP53 KRT7 CDKN2A CD8A CD4
461 bladder urothelial carcinoma 9.7 TP53 PTEN HRAS CDKN2A
462 pancytopenia 9.7 TP53 MME CD8A CD4
463 mucosal melanoma 9.7 PTEN HRAS CDKN2A CD274
464 lymphatic system cancer 9.7 TP53 MME CD8A CD4
465 lymphatic system disease 9.7 TP53 MME CD8A CD4
466 gastric adenocarcinoma 9.7 TP53 PTEN HRAS CDKN2A
467 squamous cell papilloma 9.7 TP53 KRT7 HRAS GP5 CDKN2A
468 actinic keratosis 9.7 TP53 EGFR CDKN2A CD8A CD4
469 peritoneum cancer 9.7 TP53 KRT7 EGFR CDKN2A CD274 BRCA1
470 large cell carcinoma 9.7 TP53 KRT7 HRAS EGFR
471 epidermodysplasia verruciformis 1 9.7 UBE3A TP53 GP5 CDKN2A CD8A CD4
472 lung carcinoma in situ 9.7 TP53 KRT7 HRAS EGFR
473 pulmonary adenocarcinoma in situ 9.7 TP53 KRT7 HRAS EGFR
474 blastoma 9.7 TP53 KRT7 HRAS EGFR
475 urethral benign neoplasm 9.7 TP53 PGR MME KRT7 ESR1 CALD1
476 pancreatic adenocarcinoma 9.7 TP53 HRAS EGFR CDKN2A
477 good syndrome 9.7 TP53 EGFR CD8A CD4 CD274
478 adrenal cortical carcinoma 9.7 TP53 EGFR CD8A CD274 BRCA1
479 cervical adenosarcoma 9.7 TP53 PGR MME MAPK8IP1 GP5 ESR1
480 ovarian clear cell carcinoma 9.7 TP53 PTEN HRAS BRCA1
481 bronchiolo-alveolar adenocarcinoma 9.7 TP53 KRT7 HRAS EGFR
482 adenomyoma 9.7 PGR MME KRT7 ESR1 CDKN2A CALD1
483 basal cell nevus syndrome 9.7 TP53 PTEN HRAS BRCA1
484 mature b-cell neoplasm 9.7 TP53 MME CDKN2A CD8A CD4
485 gastrointestinal system benign neoplasm 9.7 TP53 KRT7 HRAS EGFR
486 premature menopause 9.7 TP53 PTEN PGR ESR1 CD4 BRCA1
487 breast disease 9.7 TP53 PGR ESR1 BRCA1
488 gallbladder disease 9.7 TP53 KRT7 HRAS EGFR
489 cystadenofibroma 9.6 TP53 MME KRT7 HRAS
490 lung sarcomatoid carcinoma 9.6 KRT7 HRAS EGFR CD274
491 ovary epithelial cancer 9.6 TP53 PTEN HRAS BRCA1
492 synchronous bilateral breast carcinoma 9.6 TP53 PTEN PGR ESR1 EGFR BRCA1
493 lobular neoplasia 9.6 TP53 PTEN PGR ESR1 EGFR BRCA1
494 hypertrophy of breast 9.6 TP53 PTEN PGR ESR1 EGFR BRCA1
495 estrogen-receptor positive breast cancer 9.6 TP53 PTEN PGR ESR1 EGFR BRCA1
496 mature t-cell and nk-cell lymphoma 9.6 TP53 MME CD8A CD4 CD274
497 breast fibroadenoma 9.6 TP53 PGR MME ESR1 EGFR BRCA1
498 thyroid gland follicular carcinoma 9.6 TP53 PTEN KRT7 HRAS
499 cardiovascular organ benign neoplasm 9.6 TP53 PTEN KRT7 HRAS
500 endosalpingiosis 9.6 TP53 KRT7 HRAS ESR1 BRCA1
501 small cell cancer of the lung 9.6 TP53 PTEN KRT7 INSM1 EGFR CDKN2A
502 osteoporosis 9.6 TP53 PTEN PGR OGN ESR1 BRCA1
503 paraganglioma 9.6 KRT7 HRAS EGFR CDKN2A
504 testicular disease 9.6 TP53 ESR1 CD8A CD4 CD274 BRCA1
505 skin papilloma 9.6 TP53 PTEN HRAS EGFR
506 skin melanoma 9.6 TP53 PTEN HRAS CDKN2A CD274
507 chordoma 9.6 TP53 PTEN KRT7 EGFR CDKN2A CD274
508 cystadenoma 9.6 PTEN PGR MME KRT7 BRCA1
509 salivary gland disease 9.6 TP53 KRT7 EGFR CD8A CD4
510 thyroid gland anaplastic carcinoma 9.6 TP53 PTEN HRAS EGFR
511 peripheral nervous system neoplasm 9.6 TP53 PTEN HRAS EGFR
512 bone marrow cancer 9.6 TP53 HRAS CD8A CD4
513 mucinous adenocarcinoma 9.6 TP53 KRT7 HRAS EGFR CDKN2A
514 large cell neuroendocrine carcinoma 9.6 TP53 KRT7 INSM1 HRAS EGFR
515 ampulla of vater cancer 9.6 TP53 KRT7 HRAS EGFR CDKN2A
516 lung benign neoplasm 9.6 TP53 KRT7 HRAS EGFR CDKN2A
517 short syndrome 9.6 TP53 PGR ESR1 EGFR CD8A CD4
518 pleural disease 9.6 TP53 EGFR CDKN2A CD8A CD4 CD274
519 uveal disease 9.6 HRAS CD8A CD4 CD274
520 lymphoepithelioma-like carcinoma 9.6 TP53 KRT7 EGFR CDKN2A CD8A CD274
521 pleomorphic carcinoma 9.6 TP53 KRT7 HRAS EGFR CD274
522 mismatch repair cancer syndrome 9.6 TP53 PTEN HRAS CD274 BRCA1
523 intrahepatic cholangiocarcinoma 9.6 TP53 KRT7 HRAS EGFR CD274
524 bile duct adenocarcinoma 9.5 TP53 KRT7 HRAS EGFR CD274
525 breast carcinoma in situ 9.5 TP53 PTEN PGR ESR1 EGFR CDKN2A
526 ductal carcinoma in situ 9.5 TP53 PTEN PGR ESR1 EGFR CDKN2A
527 lung non-squamous non-small cell carcinoma 9.5 HRAS EGFR CD8A CD274
528 lymphoma, non-hodgkin, familial 9.5 TP53 MME CD8A CD4 CD274
529 lung adenoma 9.5 TP53 PTEN HRAS EGFR CDKN2A
530 skin squamous cell carcinoma 9.5 TP53 PTEN HRAS EGFR CDKN2A
531 giant cell glioblastoma 9.5 TP53 PTEN HRAS EGFR CDKN2A
532 intestinal benign neoplasm 9.5 TP53 PTEN HRAS EGFR CDKN2A
533 myelofibrosis 9.5 TP53 HRAS CDKN2A CD274
534 neurofibromatosis, type i 9.5 TP53 PTEN HRAS EGFR CDKN2A
535 pilocytic astrocytoma 9.5 TP53 PTEN HRAS EGFR CDKN2A
536 papillary serous adenocarcinoma 9.5 TP53 PGR KRT7 HRAS ESR1 BRCA1
537 cell type benign neoplasm 9.5 TP53 PTEN HRAS EGFR CDKN2A
538 endometrial adenocarcinoma 9.5 TP53 PTEN PGR KRT7 ESR1 EGFR
539 rasopathy 9.5 TP53 PTEN HRAS EGFR CDKN2A
540 hemangioma 9.5 TP53 PTEN PGR KRT7 ESR1 EGFR
541 deficiency anemia 9.5 TP53 MME CD8A CD4 BRCA1
542 lung cancer susceptibility 3 9.5 TP53 KRT7 HRAS EGFR CDKN2A
543 basal cell carcinoma 9.5 TP53 PTEN MME KRT7 EGFR CDKN2A
544 lung large cell carcinoma 9.5 TP53 KRT7 INSM1 HRAS EGFR CD274
545 gastroesophageal adenocarcinoma 9.4 TP53 HRAS EGFR CD8A CD274
546 cowden syndrome 1 9.4 TP53 PTEN HRAS EGFR BRCA1
547 spinal cord disease 9.4 TP53 PTEN EGFR CDKN2A CD8A CD4
548 breast lobular carcinoma 9.4 TP53 PTEN PGR KRT7 ESR1 EGFR
549 thoracic benign neoplasm 9.4 TP53 PGR MME KRT7 ESR1 EGFR
550 breast benign neoplasm 9.4 TP53 PGR MME KRT7 ESR1 EGFR
551 congenital nervous system abnormality 9.4 UBE3A TP53 PTEN CD8A CD4 BRCA1
552 leukocyte disease 9.4 TP53 MME EGFR CD8A CD4 CD274
553 cholangitis, primary sclerosing 9.4 TP53 KRT7 HRAS CD8A CD4
554 pheochromocytoma 9.4 MME KRT7 INSM1 HRAS ESR1 CDKN2A
555 malignant pleural mesothelioma 9.4 TP53 PTEN HRAS EGFR CDKN2A CD274
556 thyroid gland cancer 9.4 TP53 PTEN KRT7 HRAS EGFR
557 lung squamous cell carcinoma 9.4 TP53 PTEN HRAS EGFR CDKN2A CD274
558 muir-torre syndrome 9.4 TP53 PTEN KRT7 HRAS CDKN2A BRCA1
559 anal squamous cell carcinoma 9.4 TP53 KRT7 EGFR CDKN2A CD8A CD4
560 exanthem 9.3 HRAS EGFR CD8A CD4 CD274
561 melanoma, cutaneous malignant 1 9.3 TP53 PTEN HRAS EGFR CDKN2A BRCA1
562 penile cancer 9.3 UBE3A TP53 GP5 EGFR CDKN2A CD8A
563 respiratory system benign neoplasm 9.3 TP53 PTEN KRT7 HRAS EGFR CDKN2A
564 brain glioma 9.3 TP53 PTEN EGFR CDKN2A CD8A CD4
565 meningioma, familial 9.3 TP53 PTEN PGR HRAS ESR1 EGFR
566 integumentary system disease 9.3 TP53 HRAS EGFR CD8A CD4 CD274
567 female reproductive endometrioid cancer 9.3 TP53 PTEN PGR KRT7 HRAS ESR1
568 li-fraumeni syndrome 9.2 TP53 PTEN HRAS ESR1 EGFR CDKN2A
569 leukemia, acute lymphoblastic 9.2 TP53 MME HRAS CDKN2A CD8A CD4
570 medulloblastoma 9.2 TP53 PTEN INSM1 HRAS EGFR CDKN2A
571 small intestine cancer 9.2 TP53 PTEN KRT7 HRAS EGFR CDKN2A
572 gallbladder cancer 9.2 TP53 PTEN KRT7 HRAS EGFR CDKN2A
573 lymphangioma 9.2 TP53 KRT7 HRAS EGFR CD8A CD4
574 cholangiocarcinoma 9.2 TP53 PTEN MME KRT7 EGFR CDKN2A
575 serous cystadenocarcinoma 9.1 TP53 PTEN PGR KRT7 HRAS ESR1
576 pancreatic ductal carcinoma 9.1 TP53 KRT7 HRAS EGFR CDKN2A CD8A
577 thymoma 9.1 TP53 KRT7 HRAS EGFR CDKN2A CD8A
578 cowden syndrome 9.1 TP53 PTEN PGR HRAS ESR1 EGFR
579 hereditary breast ovarian cancer syndrome 9.1 TP53 PTEN PGR HRAS ESR1 EGFR
580 uterine benign neoplasm 9.1 TP53 PTEN PGR MME HRAS ESR1
581 muscle cancer 9.1 TP53 PTEN MME HRAS EGFR CDKN2A
582 neuroblastoma 9.1 TP53 PTEN HRAS ESR1 EGFR CDKN2A
583 suppression of tumorigenicity 12 9.1 TP53 PTEN HRAS EGFR CDKN2A CD8A
584 gliosarcoma 9.1 TP53 PTEN HRAS EGFR CDKN2A CD8A
585 uterine carcinosarcoma 9.1 TP53 PTEN HRAS ESR1 EGFR CD8A
586 rectum adenocarcinoma 9.1 TP53 KRT7 HRAS EGFR CD8A CD4
587 mantle cell lymphoma 9.0 TP53 PTEN MME EGFR CDKN2A CD8A
588 ovarian serous cystadenocarcinoma 9.0 TP53 PTEN HRAS EGFR CDKN2A CD8A
589 bladder cancer 9.0 TP53 PTEN KRT7 HRAS ESR1 EGFR
590 adenoid cystic carcinoma 9.0 TP53 PTEN PGR KRT7 HRAS EGFR
591 thymus gland disease 9.0 TP53 PTEN HRAS EGFR CD8A CD4
592 colorectal adenocarcinoma 9.0 TP53 PTEN KRT7 HRAS EGFR CD8A
593 renal cell carcinoma, papillary, 1 8.9 TP53 PTEN MME KRT7 HRAS EGFR
594 reproductive organ benign neoplasm 8.9 TP53 PTEN PGR MME KRT7 HRAS
595 head and neck cancer 8.9 TP53 PTEN HRAS EGFR CDKN2A CD8A
596 bile duct cancer 8.9 TP53 PTEN KRT7 HRAS EGFR CDKN2A
597 rectal disease 8.8 TP53 KRT7 HRAS GP5 EGFR CDKN2A
598 gastrointestinal stromal tumor 8.8 TP53 PTEN HRAS ESR1 EGFR CDKN2A
599 carcinosarcoma 8.8 TP53 PTEN PGR MME KRT7 HRAS
600 ovarian cystadenocarcinoma 8.8 TP53 PTEN HRAS ESR1 EGFR CDKN2A
601 thymus cancer 8.8 TP53 PTEN KRT7 HRAS EGFR CD8A
602 ovarian cancer 8.8 TP53 PTEN PGR KRT7 HRAS ESR1
603 skin disease 8.8 TP53 PTEN HRAS ESR1 EGFR CDKN2A
604 melanoma, uveal 8.7 TP53 PTEN HRAS EGFR CDKN2A CD8A
605 uterine body mixed cancer 8.7 TP53 PTEN HRAS ESR1 EGFR CD8A
606 colonic benign neoplasm 8.7 TP53 PTEN KRT7 HRAS ESR1 EGFR
607 anus disease 8.7 UBE3A TP53 KRT7 HRAS GP5 EGFR
608 retinitis pigmentosa 8.7 TP53 PTEN HRAS ESR1 EGFR CDKN2A
609 malignant ovarian surface epithelial-stromal neoplasm 8.7 TP53 PTEN KRT7 HRAS ESR1 EGFR
610 skin carcinoma 8.7 TP53 PTEN KRT7 HRAS EGFR CDKN2A
611 leukemia, chronic lymphocytic 8.6 TP53 PTEN MME HRAS EGFR CDKN2A
612 eye disease 8.6 TP53 PTEN HRAS ESR1 EGFR CDKN2A
613 esophageal cancer 8.6 TP53 PTEN HRAS ESR1 EGFR CDKN2A
614 ovary adenocarcinoma 8.6 TP53 PTEN PGR KRT7 HRAS ESR1
615 chromophobe renal cell carcinoma 8.5 TP53 PTEN MME KRT7 HRAS EGFR
616 pre-malignant neoplasm 8.5 TP53 PTEN PGR KRT7 INSM1 HRAS
617 uterine corpus cancer 8.5 TP53 PTEN PGR HRAS ESR1 EGFR
618 mixed cell type cancer 8.5 TP53 PTEN PGR MME KRT7 HRAS
619 endocervical adenocarcinoma 8.5 TP53 PTEN PGR MAPK8IP1 KRT7 INSM1
620 lynch syndrome 8.5 TP53 PTEN PGR KRT7 HRAS ESR1
621 peripheral nervous system disease 8.3 TP53 PTEN MME HRAS ESR1 EGFR
622 nervous system disease 8.3 TP53 PTEN MME HRAS ESR1 EGFR
623 breast adenocarcinoma 8.3 TP53 PTEN PGR KRT7 HRAS ESR1
624 endocervical carcinoma 8.2 TP53 PTEN PGR MAPK8IP1 KRT7 INSM1
625 oropharynx cancer 8.2 UBE3A TP53 PTEN PGR KRT7 HRAS
626 renal cell carcinoma, nonpapillary 8.1 TP53 PTEN MME KRT7 HRAS ESR1
627 wilms tumor 1 8.0 TP53 PTEN PGR MME KRT7 HRAS

Comorbidity relations with Vaginal Cancer via Phenotypic Disease Network (PDN): (showing 4, show less)


Acute Cystitis Cervical Cancer
Deficiency Anemia Vulva Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:



Diseases related to Vaginal Cancer

Symptoms & Phenotypes for Vaginal Cancer

UMLS symptoms related to Vaginal Cancer:


pelvic pain; vaginal pruritus

MGI Mouse Phenotypes related to Vaginal Cancer:

45 (showing 16, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 BRCA1 CD274 CD4 CDKN2A EGFR ESR1
2 nervous system MP:0003631 10.37 BRCA1 CD4 CD8A CDKN2A EGFR ESR1
3 cellular MP:0005384 10.31 BRCA1 CD274 CD4 CD8A CDKN2A EGFR
4 endocrine/exocrine gland MP:0005379 10.27 BRCA1 CD4 CD8A CDKN2A EGFR ESR1
5 no phenotypic analysis MP:0003012 10.24 CD274 CD4 CDKN2A EGFR ESR1 HRAS
6 neoplasm MP:0002006 10.21 BRCA1 CDKN2A EGFR ESR1 HRAS LRIG2
7 normal MP:0002873 10.2 BRCA1 CD8A EGFR ESR1 GP5 HRAS
8 behavior/neurological MP:0005386 10.18 BRCA1 CD274 CDKN2A ESR1 HRAS LRIG2
9 renal/urinary system MP:0005367 10.16 BRCA1 CALD1 CD8A EGFR ESR1 HRAS
10 muscle MP:0005369 10.15 BRCA1 CALD1 CDKN2A EGFR ESR1 HRAS
11 immune system MP:0005387 10.13 BRCA1 CD274 CD4 CD8A CDKN2A EGFR
12 digestive/alimentary MP:0005381 10.09 BRCA1 CD4 CDKN2A EGFR ESR1 HRAS
13 respiratory system MP:0005388 9.86 BRCA1 CDKN2A EGFR ESR1 HRAS INSM1
14 mortality/aging MP:0010768 9.86 BRCA1 CALD1 CD274 CD4 CD8A CDKN2A
15 skeleton MP:0005390 9.85 BRCA1 CD274 CDKN2A EGFR ESR1 HRAS
16 integument MP:0010771 9.5 BRCA1 CD274 CD4 CD8A CDKN2A EGFR

Drugs & Therapeutics for Vaginal Cancer

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 87, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
2
Ondansetron Approved Phase 3 99614-02-5 4595
3
Granisetron Approved, Investigational Phase 3 109889-09-0 3510 5284566
4
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
5 Immunologic Factors Phase 3
6 Vaccines Phase 3
7 Dermatologic Agents Phase 3
8 Gastrointestinal Agents Phase 3
9 Antineoplastic Agents, Hormonal Phase 3
10 Antiemetics Phase 3
11 Antipsychotic Agents Phase 3
12 Anti-Anxiety Agents Phase 3
13 Emetics Phase 3
14
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
17
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
18
Aldesleukin Approved Phase 2 110942-02-4
19
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
20
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
21
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
22
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
23
Fondaparinux Approved, Investigational Phase 2 114870-03-0, 104993-28-4 5282448 636380
24
Bupropion Approved Phase 2 31677-93-7, 34841-39-9, 34911-55-2 444
25
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
26
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
27
Avelumab Approved, Investigational Phase 2 1537032-82-8
28
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
29
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
30 Albumin-Bound Paclitaxel Phase 2
31 Anti-Infective Agents Phase 2
32 Antiviral Agents Phase 2
33 Anti-HIV Agents Phase 2
34 Antineoplastic Agents, Alkylating Phase 2
35 Antirheumatic Agents Phase 2
36 Anti-Retroviral Agents Phase 2
37 Immunosuppressive Agents Phase 2
38 Alkylating Agents Phase 2
39 Cyclosporins Phase 2
40 Antifungal Agents Phase 2
41 Calcineurin Inhibitors Phase 2
42 Antitubercular Agents Phase 2
43 Antibiotics, Antitubercular Phase 2
44 Anti-Bacterial Agents Phase 2
45 Tubulin Modulators Phase 2
46 Antimitotic Agents Phase 2
47 Factor Xa Inhibitors Phase 2
48 Fibrinolytic Agents Phase 2
49 Serine Proteinase Inhibitors Phase 2
50 Antithrombins Phase 2
51 Antithrombin III Phase 2
52
protease inhibitors Phase 2
53 Anticoagulants Phase 2
54 HIV Protease Inhibitors Phase 2
55 PENTA Phase 2
56 Cytochrome P-450 Enzyme Inhibitors Phase 2
57 Antidepressive Agents Phase 2
58 Dopamine Uptake Inhibitors Phase 2
59 Dopamine Agents Phase 2
60 Psychotropic Drugs Phase 2
61 Anticonvulsants Phase 2
62 Immunoglobulins, Intravenous Phase 2
63 Immunoglobulin G Phase 2
64 Angiogenesis Inhibitors Phase 2
65 Interleukin-12 Phase 2
66 Adjuvants, Immunologic Phase 2
67 topoisomerase I inhibitors Phase 2
68 Neurotransmitter Agents Phase 2
69
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
70
Carboplatin Approved Phase 1 41575-94-4 10339178 38904
71
Trastuzumab Approved, Investigational Phase 1 180288-69-1
72
Topotecan Approved, Investigational Phase 1 123948-87-8, 119413-54-6 60699 60700
73
Vinorelbine Approved, Investigational Phase 1 71486-22-1 44424639 60780
74
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
75
Gemcitabine Approved Phase 1 95058-81-4, 122111-03-9 60750
76
Talazoparib Approved, Investigational Phase 1 1207456-01-6 135565082
77
Durvalumab Approved, Investigational Phase 1 1428935-60-7
78
MK-1775 Investigational Phase 1 955365-80-7 24856436
79
Tremelimumab Investigational Phase 1 745013-59-6
80 Radiopharmaceuticals Phase 1
81 Fluorodeoxyglucose F18 Phase 1
82 Deoxyglucose Phase 1
83 Fluorides Phase 1
84 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
85
Formaldehyde Approved, Vet_approved 50-00-0 712
86
Coal tar Approved 8007-45-2
87 Estrogens

Interventional clinical trials:

(showing 98, show less)
# Name Status NCT ID Phase Drugs
1 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
2 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Completed NCT04425291 Phase 3
3 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years Completed NCT05372016 Phase 3
4 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
5 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
6 A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) Completed NCT00943722 Phase 3
7 A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND) Completed NCT00003267 Phase 3
8 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
9 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Completed NCT01536392 Phase 3 Granisetron;Ondansetron
10 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
11 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
12 A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™ Completed NCT01047345 Phase 3
13 Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial Recruiting NCT04895020 Phase 3
14 Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial Recruiting NCT05027776 Phase 3
15 A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Recruiting NCT04422366 Phase 3
16 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Active, not recruiting NCT02466971 Phase 3 Cisplatin;Triapine
17 Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study Unknown status NCT00905658 Phase 2
18 A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer Completed NCT00941070 Phase 2 triapine;cisplatin
19 A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies Completed NCT01079832 Phase 2
20 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
21 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
22 A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO) Completed NCT01399658 Phase 2 3'-Deoxy-3'-18f-Fluorothymidine
23 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2
24 A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women Completed NCT00551187 Phase 2
25 A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
26 Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer. Completed NCT00275353 Phase 2
27 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
28 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
29 EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA Completed NCT00002562 Phase 2 paclitaxel
30 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
31 A Pilot Study of Conformal Intensity Modulated Radiation Therapy (IMRT) for Gynaecological Cancer Patients Not Suitable for Intracavitary Brachytherapy Boost (GY03.2) Completed NCT00188578 Phase 1, Phase 2
32 Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer Completed NCT03180294 Phase 2 Bupropion 150 mg XL;Placebo
33 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
34 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Active, not recruiting NCT03439085 Phase 2
35 A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
36 A Phase II Study of Sacral Nerve Stimulation for Low Anterior Resection Syndrome or Fecal Incontinence in Patients Following a Low Anterior Resection or Proctectomy With Coloanal Anastomosis or in Patients After Pelvic Chemoradiation (RESTORE) Terminated NCT04066894 Phase 2
37 A Phase I/II Feasibility/Efficacy Study of HIFU in Otherwise Untreatable Pelvic Rectal Cancer Withdrawn NCT01097239 Phase 1, Phase 2
38 A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
39 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
40 Phase I Study of Intravenous Triapine® (IND #68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies. Completed NCT00335998 Phase 1 triapine;cisplatin
41 A Phase I Study of Weekly Oral Topotecan in Gynecologic Malignancies Completed NCT00842452 Phase 1 topotecan hydrochloride
42 Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy Completed NCT02058550 Phase 1
43 A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX) Completed NCT00851643 Phase 1
44 Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies Completed NCT00002949 Phase 1 paclitaxel;vinorelbine tartrate
45 Phase I Study of Metronomic Daily Dosing of Docetaxel in Women With Progressive or Recurrent Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
46 A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years Completed NCT03676101 Phase 1
47 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
48 MRI Guided Brachytherapy for HPV-Associated Cervical and Vaginal Malignancies Recruiting NCT03634267 Phase 1
49 Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer Recruiting NCT02595879 Phase 1 Cisplatin;Triapine
50 Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers Recruiting NCT03968406 Phase 1 Talazoparib
51 Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer Active, not recruiting NCT03452332 Phase 1
52 A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735) Active, not recruiting NCT03345784 Phase 1 Adavosertib;Cisplatin
53 A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer Terminated NCT03277482 Phase 1 Durvalumab;Tremelimumab
54 Phase I Study of Capecitabine (Xeloda) and Radiation Therapy in Patients With Locally Advanced Cervical and Pelvic Malignancies Withdrawn NCT00118300 Phase 1 capecitabine
55 SPARC Study: A Nurse-led Sexual Rehabilitation Programme for Women With Gynaecological Cancers Receiving Radiotherapy: a Randomized Multicentre Trial Unknown status NCT03611517
56 Evaluation of Bone Density and Pelvic Fractures in Women Undergoing Definitive Pelvic Radiation Therapy for Cervical, Endometrial or Vaginal Cancer Unknown status NCT00800644
57 Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER) Unknown status NCT00601406
58 Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study Unknown status NCT00005095
59 Developing a Stepped Approach to Improving Sexual Function After Gynaecological Cancer- a Feasibility Study and Randomized Controlled Trial Unknown status NCT02458001
60 Gynecologic Cancer Survivorship Survey Unknown status NCT00391664
61 Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer Completed NCT00897442
62 Piloting a Serious Game to Improve Self-Advocacy Among Women With Advanced Cancer Completed NCT03339765
63 Does a Post Treatment Survivorship Care Plan Improve Gynaecological Cancer Patient's Quality of Life and Self Efficacy? A Mixed Methods Pilot Study. Completed NCT01582906
64 The Rehabilitation Needs of People Who Have Had an Upper Gastrointestinal or a Gynecological Cancer Completed NCT01216813
65 Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer Completed NCT02096783
66 Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance Completed NCT00581646
67 Electronic Patient-Reported Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life Completed NCT00870233
68 Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life Completed NCT00578006
69 Lymphoscintigraphy and Selective Lymphatic Mapping in Patients With Invasive Vaginal Cancer Completed NCT00528034
70 A Pilot Study Using the Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema Completed NCT00944944
71 Immediate Vaginal Reconstruction Following Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function Completed NCT00588081
72 Integrating a Health Information Technology System With a Web-based Mobile Health Educational Intervention to Support More Effective Provider-patient Communication and HPV Vaccine Utilization Completed NCT03346915
73 Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU): A Feasibility Study for Treating Recurrent Gynaecological Malignancies Completed NCT02714621
74 Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina Completed NCT01703195
75 Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy Completed NCT03956498
76 The Validation of Two Inpatient Adult Nutrition Screening Tools in Cancer Care - a Prospective Study Completed NCT01851928
77 A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence Completed NCT01764789
78 Pilot Study of Magnetic Resonance Imaging Guided Brachytherapy Completed NCT00112307
79 Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology Completed NCT04351139
80 A Randomized Study to Evaluate the Effect of Outpatient Symptom Management on Symptom Burden in Advanced Stage or Recurrent Gynecologic Oncology Patients Receiving Chemotherapy Completed NCT02786524
81 Fractional CO2 Laser Therapy for Survivors of Gynecologic Malignancies Completed NCT03372720
82 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
83 Counseling Intervention During Radiation Therapy for Women With Gynecologic Cancer Recruiting NCT04269837
84 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
85 A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite Recruiting NCT02993900
86 The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Recruiting NCT04028479 Systemic Treatment (T)
87 Primary Organoid Models and Combined Nucleic Acids Therapeutics for Innovative Anti-HPV Treatments in Cervico-vaginal Cancers and Precancerous Lesions Recruiting NCT04278326
88 Randomised Controlled Feasibility Trial Evaluating the Effectiveness of Mindfulness Compared to Exercise and Mindfulness on Fatigue in Women With Gynaecology Cancer Recruiting NCT05561413
89 A Retrospective Study of Brachytherapy in Gynecological Cancers Recruiting NCT05242861
90 Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation Recruiting NCT04626466
91 Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy Recruiting NCT00791635
92 Detection of Sentinel Lymph Nodes in Female Lower Genital Tract Cancer Patients With Contrast-Enhanced Ultrasound Imaging Recruiting NCT05105087 Early Phase 1 Perflubutane Microbubble
93 Longitudinal Changes in Women's Pelvic Health and Sexual Function After Pelvic Radiation Recruiting NCT04713618
94 A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women Active, not recruiting NCT02653118
95 Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial Not yet recruiting NCT05371353
96 ChemoFx® PRO - A Post-Market Data Collection Study Utilizing Physician Reported Outcomes Terminated NCT00669422
97 Quality of Life Outcomes From a Peer-to-Peer Support Program for Women With Gynecologic Cancer Terminated NCT02412124
98 Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia Withdrawn NCT01313104

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Genetic Tests for Vaginal Cancer

Anatomical Context for Vaginal Cancer

Organs/tissues related to Vaginal Cancer:

FMA: Vagina
MalaCards : Cervix, Uterus, Breast, Bone, Lymph Node, Bone Marrow, Ovary

Publications for Vaginal Cancer

Articles related to Vaginal Cancer:

(showing 1025, show less)
# Title Authors PMID Year
1
Innovations in the Management of Vaginal Cancer. 62 41
35621640 2022
2
Primary vaginal endodermal sinus tumor in infants and children: experience from a tertiary center. 41
36207682 2022
3
Trends in the Incidence of Vulvar and Vaginal Cancers With Different Histology by Race, Age, and Region in the United States (2001-2018). 41
36105176 2022
4
Pelvic organ prolapse and vaginal cancer: A systematic literature review. 62
35167139 2022
5
Postmenopausal Vaginal and Cervical Cancer Risk Related to In Utero Diethylstilbestrol Exposure. 62
36222810 2022
6
Outcomes of 3D MRI based HDR brachytherapy with hybrid multichannel vaginal cylinder applicator and freehand needles for treatment of vaginal disease. 62
36266203 2022
7
Pap smear outcomes in elderly women living with HIV and HIV-negative matched controls. 62
35980835 2022
8
A modern-day experience with Brunschwig's operation: Outcomes associated with pelvic exenteration. 62
36064678 2022
9
Cellular angiofibroma of the vagina: A case report and literature review. 62
36107545 2022
10
Intensity-modulated brachytherapy for vaginal cancer. 62
36069978 2022
11
Factors that affect survival in vaginal cancer: a seer analysis. 62
35543117 2022
12
Our clinical experience in pelvic magnetic resonance imaging with vaginal contrast. 62
35997217 2022
13
Vaginal yolk sac tumor resected by a novel laparo/endoscope-assisted posterior sagittal approach: a case report. 62
36036317 2022
14
Protein Expression Profiling and Virtual Drug Screening as an Approach for Individualized Therapy of Small Cell Vaginal Carcinoma. 62
35732326 2022
15
Implementation of Image-Guided Brachytherapy for Pediatric Vaginal Cancers: Feasibility and Early Clinical Results. 62
35805018 2022
16
Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014. 62
35633031 2022
17
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. 62
35248212 2022
18
First clinical experience with a novel, mobile cone-beam CT system for treatment quality assurance in brachytherapy. 62
35278094 2022
19
Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis. 62
35551568 2022
20
Second primary malignancies in cervical cancer and endometrial cancer survivors: a population-based analysis. 62
35507749 2022
21
[Analysis on cancer incidence and mortality attributed to human papillomavirus infection in China, 2016]. 62
35589576 2022
22
A lipidic mesophase with tunable release properties for the local delivery of macromolecules: the apoferritin nanocage, a case study. 62
35470843 2022
23
[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors]. 62
35658326 2022
24
Primary Vaginal Adenocarcinoma of Intestinal-Type: A Case Report of a Rare Tumor With Review of Histology, Differential Diagnosis, and Literature. 62
35755502 2022
25
Malignant mesenchymal vaginal tumor mimicking pedunculated submucous myoma: A case report. 62
35318185 2022
26
Vaginal leiomyoma mimicking a Cystocele (report case). 62
35364392 2022
27
Primary poorly differentiated carcinoma of the vagina with focal neuroendocrine differentiation: a tumour with aggressive behaviour. 62
35396236 2022
28
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. 62
35428697 2022
29
Vaginal cancer: Why should we care? Anatomy, staging and in-depth imaging-based review of vaginal malignancies focusing on MRI and PET/CT. 62
35151129 2022
30
Assessing the Effectiveness of Web-Based Modules on Human Papillomavirus Among Dental and Dental Hygiene Students. 62
35296971 2022
31
18F-FDG PET/CT in Patients with Vulvar and Vaginal Cancer: A Preliminary Study of 20 Cases. 62
34818510 2022
32
Patient perspectives and experiences of the rapid implementation of digital consultations during COVID-19 - a qualitative study among women with gynecological cancer. 62
34796401 2022
33
Updates in the treatment of vaginal cancer. 62
35256422 2022
34
Combined modality including novel sensitizers in gynecological cancers. 62
35256428 2022
35
Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. 62
34974906 2022
36
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013. 62
35026864 2022
37
BEBIG 60Co HDR brachytherapy source dosimetric parameters validation using GATE Geant4-based simulation code. 62
35368537 2022
38
Benign mixed Müllerian (duct) vaginal tumor in a 12-y-old goat. 62
35000511 2022
39
Bevacizumab increases late toxicity in re-irradiation with image-guided high-dose-rate brachytherapy for gynecologic malignancies. 62
35233235 2022
40
Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications? 62
35159024 2022
41
Role of radiotherapy in the treatment of primary vaginal cancer: Recommendations of the French society for radiation oncology. 62
34955415 2022
42
Surgical management of vaginal cancer and concomitant complete uterovaginal prolapse. 62
34735589 2022
43
Development and validation of models for predicting the overall survival and cancer-specific survival of patients with primary vaginal cancer: A population-based retrospective cohort study. 62
36106318 2022
44
Trends in Incidence and Mortality of Gynecological and Breast Cancers in Poland (1980-2018). 62
35115839 2022
45
A Comprehensive Discussion in Vaginal Cancer Based on Mechanisms, Treatments, Risk Factors and Prevention. 62
35924174 2022
46
Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma. 62
34868367 2022
47
Superficial myofibroblastoma of the vagina with a stalk: case report of a rare vaginal tumor with notable radiological findings. 62
34630802 2021
48
The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: A systematic review. 62
34546565 2021
49
Gynecologic tumor board: a radiologist's guide to vulvar and vaginal malignancies. 62
34435227 2021
50
Feasibility of bone marrow sparing volumetric modulated arc therapy to spare active bone marrow in cervical and vaginal cancer patients: a retrospective dosimetric analysis. 62
34288534 2021
51
Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. 62
35149535 2021
52
Case series: Vaginal pessary for pelvic organ prolapse and its association with vaginal cancer. 62
34806683 2021
53
Vaginal cancer diagnosed during pregnancy presenting a therapeutic dilemma: A case report. 62
34926760 2021
54
Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review. 62
34926759 2021
55
Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. 62
34518053 2021
56
Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors. 62
34724840 2021
57
Vaginal high-grade sarcoma in pregnancy. 62
34926762 2021
58
A custom-made brachytherapy applicator for recurrent endometrial and vaginal cancer: A dental technique for prosthesis fabrication. 62
33162114 2021
59
ACR Appropriateness Criteria® Staging and Follow-up of Primary Vaginal Cancer. 62
34794599 2021
60
Cancer of the vagina: 2021 update. 62
34669198 2021
61
Primary pelvic exenteration: Our experience with 23 patients from a single institution. 62
34434274 2021
62
The Lifetime Cost Estimation of Human Papillomavirus-related Diseases in China: A Modeling Study. 62
34900631 2021
63
Effects of brachytherapy on cytogenetic parameters and oxidative status in peripheral blood lymphocytes of gynecologic cancer patients. 62
34591418 2021
64
New developments in rare vulvar and vaginal cancers. 62
34319290 2021
65
[Application of vaginoscopy in the diagnosis and treatment of occult vaginal high-grade squamous intraepithelial lesions]. 62
34420289 2021
66
An anthropomorphic deformable phantom of the vaginal wall and cavity. 62
34298530 2021
67
Assessment of an onco-sexology support and follow-up program in cervical or vaginal cancer patients undergoing brachytherapy. 62
33411047 2021
68
Pyogenic Spondylitis in Multidisciplinary Therapies of Gynecologic Malignancies: Three Cases Reports. 62
34216487 2021
69
The multistep process of vaginal cancer arising from deep infiltrating endometriosis: a case report. 62
34247612 2021
70
Vaginal cancer as a late complication of radiotherapy for endometrial cancer and ileo-perineal fistula after total pelvic exenteration. 62
34085797 2021
71
Outcomes by Race Among Women Referred to an Academic Colposcopy Clinic with a Patient Navigation Program. 62
32960144 2021
72
Incidence of human papillomavirus-related anogenital precancer and cancer in women with diabetes: A nationwide registry-based cohort study. 62
33129233 2021
73
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012. 62
33631867 2021
74
Clinical presentation, treatment, and outcomes associated with vaginal intraepithelial neoplasia: A retrospective study of 118 patients. 62
33754436 2021
75
Transvaginal natural orifice transluminal endoscopic surgery (vNOTES) as treatment for upper vaginal leiomyoma: A case report. 62
34011080 2021
76
Magnetic Resonance Imaging of Uterine Cervix: A Pictorial Essay. 62
34556931 2021
77
New frontiers of developmental endocrinology opened by researchers connecting irreversible effects of sex hormones on developing organs. 62
33189416 2021
78
Uterine transposition for gynecological cancers. 62
33649011 2021
79
Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer: Results of the International Multicenter RetroEMBRAVE Cohort Study. 62
33806733 2021
80
Promotion of Cervical Screening among Long-term Non-attendees by Human Papillomavirus Self-sampling. 62
33842403 2021
81
[Interdisciplinary S2k guidelines on the diagnosis and treatment of vaginal carcinoma and its precursors-recommendations on surgical pathology for histopathological workup, diagnostics, and reporting]. 62
33346872 2021
82
Primary vaginal cancer associated with HPV 68: A case report of an unusual presentation. 62
32862465 2021
83
Porphyria cutanea tarda exacerbation as a paraneoplastic syndrome in vaginal cancer resolved with chemoradiation. 62
33426257 2021
84
[A case of obstructive jaundice and duodenal stenosis caused by vaginal cancer and retroperitoneal metastasis]. 62
34108357 2021
85
3D image-guided interstitial brachytherapy for primary vaginal cancer: A multi-institutional experience. 62
33162177 2021
86
Multidisciplinary management of patients with pubic osteomyelitis, a rare but serious complication after surgery and radiation therapy for advanced gynaecological cancer. 62
33431443 2021
87
Twenty years' experience of primary vaginal cancer treatment at one cancer centre: does residence status matter? 62
34567252 2021
88
Screening History in Vaginal Precancer and Cancer: A Retrospective Study of 2131 Cases in China. 62
34858059 2021
89
The impact of brachytherapy boost and radiotherapy treatment duration on survival in patients with vaginal cancer treated with definitive chemoradiation. 62
33008762 2021
90
A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. 62
32338316 2021
91
IRIDIUM-192 RADIOTHERAPY BENEFITS IN THE MANAGEMENT OF GYNECOLOGICAL TUMORS. 62
33361862 2020
92
Prolapsed epiploica of bowel after robotic hysterectomy: A case report. 62
33145023 2020
93
Survival benefit of vaginectomy compared to local tumor excision in women with FIGO stage I and II primary vaginal carcinoma: a SEER study. 62
32780160 2020
94
Primary Vaginal Carcinoma Arising on Cystocele Mimicking Vulvar Cancer. 62
32446632 2020
95
Diagnostic benefit of cytological and histopathological examinations for recurrent vaginal cancer metastasizing to the duodenum: A case report. 62
33363849 2020
96
Occult vaginal cancer recurrence after hysterectomy: a case report and literature review. 62
33275476 2020
97
Recurrent Extra-gastrointestinal Stromal Tumor of the Vagina: A Case Report and Review of the Literature. 62
33355835 2020
98
Gynecological cancers and the global COVID-19 pandemic 62
33274617 2020
99
Paraganglioma of the Vagina Associated With Germline SDHB Mutation: Report of a Case With Review of the Literature. 62
31851064 2020
100
Geographic and temporal variations in the incidence of vulvar and vaginal cancers. 62
32410226 2020
101
Survival and prognostic factors in primary vaginal cancer: an analysis of 2004-2014 SEER data. 62
35117314 2020
102
Management options for vaginal intraepithelial neoplasia. 62
32602195 2020
103
Management and outcomes of primary vaginal Cancer. 62
32972784 2020
104
Clinical Characteristics and Long-Term Follow-up of Patients Treated for High-Grade Vaginal Intraepithelial Neoplasia: Results From a 20-Year Survey in Italy. 62
32881786 2020
105
Application of 5-aminolevulinic acid photodynamic therapy for vaginal intraepithelial neoplasia, a report of six cases. 62
32473400 2020
106
Outcomes of freehand interstitial brachytherapy in advanced gynecologic malignancies. 62
32466952 2020
107
CD4 Trajectory Models and Onset of Non-AIDS-Defining Anal Genital Warts, Precancer, and Cancer in People Living With HIV Infection-1. 62
32530855 2020
108
Surgical treatment of complete uterovaginal prolapse and concomitant vaginal cancer: a video case report. 62
32125490 2020
109
Positive sentinel lymph node in a patient with clinical stage I vaginal cancer. 62
32596436 2020
110
Laparoendoscopic single-site inguinal lymphadenectomy in gynecology: preliminary experience at a single institution. 62
32556531 2020
111
Outcomes of vaginal squamous cell carcinoma of patients treated with radiation therapy: a series of 37 patients from a single expert center. 62
31873914 2020
112
Surgical outcomes of early-stage primary vaginal nonsquamous cell carcinoma. 62
32219631 2020
113
Pelvic radiation therapy with volumetric modulated arc therapy and intensity-modulated radiotherapy after renal transplant: A report of 3 cases. 62
32494227 2020
114
Effective combination of lymphatico-venous anastomosis and negative pressure wound therapy for lymphocyst: A Case Study. 62
32464690 2020
115
Palliative treatment with electrochemotherapy in recurrent or metastatic vaginal cancer. 62
32474450 2020
116
Gynecologic cancer in pregnancy. 62
32268951 2020
117
Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. 62
32125711 2020
118
Clinical outcomes of transarterial chemotherapy and embolization for vaginal cancer. 62
32144875 2020
119
Clinical outcomes of vaginectomy and laser ablation for the treatment of post-hysterectomy women with vaginal high-grade squamous intraepithelial lesions: A retrospective study. 62
32199295 2020
120
An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers. 62
32405522 2020
121
Locally-advanced vaginal cancer with complete utero-vaginal prolapse. 62
32139436 2020
122
[Preliminary study of the clinical value of colposcopy in diagnosing vagina invasion in cervical cancer]. 62
32464720 2020
123
Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer. 62
31874348 2020
124
Using a pessary during radiotherapy in reducible pelvic organ prolapse and vaginal cancer: a case report and review of the literature. 62
32395142 2020
125
The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: scoping review. 62
32321580 2020
126
The costs of treating vaginal and vulval cancer in England (2009-2015). 62
32252711 2020
127
Accuracy of colposcopic findings in detecting vaginal intraepithelial neoplasia: a retrospective study. 62
31993733 2020
128
Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. 62
31769577 2020
129
The risk of vaginal cancer is associated with a history of cervical neoplasia. 62
31863542 2020
130
Muir-Torre Syndrome With a Frame-shift Mutation in the MSH2 Gene: A Rare Case Report and Literature Review. 62
32039937 2020
131
Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer. 62
32135119 2020
132
Hyaluronic acid gel injection in rectovaginal septum reduced incidence of rectal bleeding in brachytherapy for gynecological malignancies. 62
31879238 2020
133
Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. 62
31959338 2020
134
Photodynamic Therapy for Photodamage, Actinic Keratosis, and Acne in the Cosmetic Practice. 62
31779937 2020
135
Vulvar and vaginal neoplasia in women with inflammatory bowel disease. 62
31718933 2020
136
Vaginal carcinoma after cervical dysplasia. 62
31911538 2020
137
Rare case of pregnancy with vaginal adenocarcinoma. 62
32623043 2020
138
Radiotherapy Plus Chemotherapy Is Associated With Improved Survival Compared to Radiotherapy Alone in Patients With Primary Vaginal Carcinoma: A Retrospective SEER Study. 62
33392073 2020
139
Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations. 62
32922389 2020
140
Vaginal Intraepithelial Neoplasia: A Retrospective Study of Treatment and Outcomes Among a Cohort of UK Women. 62
31860574 2020
141
The Role of Eicosanoids in Gynecological Malignancies. 62
32982722 2020
142
Nail squamous cell carcinoma: A hidden high-risk human papillomavirus reservoir for sexually transmitted infections. 62
30930083 2019
143
Robotic type II B posterior exenteration for recurrent vaginal cancer. 62
31345607 2019
144
Anterior Pelvic Exenteration for Chemo-irradiated Non-diethylstilbestrol Exposed Clear Cell Vaginal Cancer. 62
31662571 2019
145
Neovaginoplasty for radiation-induced vaginal stenosis using Nile Tilapia Fish Skin as a biological graft. 62
31768241 2019
146
Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. 62
31718338 2019
147
Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases. 62
31662557 2019
148
Prognostic Significance of P16 Expression and P53 Expression in Primary Vaginal Cancer. 62
31593028 2019
149
Vaginal Carcinoma with Third-Degree Uterine Prolapse. 62
31681552 2019
150
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018). 62
31680701 2019
151
Primary vaginal adenocarcinoma of intestinal-type: case report of a rare gynaecological tumour. 62
31772753 2019
152
Familial Clustering, Second Primary Cancers and Causes of Death in Penile, Vulvar and Vaginal Cancers. 62
31413311 2019
153
Total Colpectomy Increases the Risk of Postoperative Hydronephrosis in Vaginal Cancer Patients. 62
29469636 2019
154
Use of multifunctional composite nanofibers for photothermalchemotherapy to treat cervical cancer in mice. 62
31290862 2019
155
Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina. 62
30561092 2019
156
Isolated Vaginal Recurrence of Early-Stage Rectal Cancer Detected by 18F-FDG PET/CT. 62
30985425 2019
157
A Systematic Assessment of Google Search Queries and Readability of Online Gynecologic Oncology Patient Education Materials. 62
29353371 2019
158
The healthcare costs of treating human papillomavirus-related cancers in Norway. 62
31064346 2019
159
Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. 62
30792003 2019
160
Radiation therapy for vaginal cancer in complete uterine prolapse with intrauterine adhesion: a case report. 62
31122220 2019
161
Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas. 62
30907776 2019
162
Diagnosis of Primary Clear Cell Carcinoma of the Vagina by 18F-FDG PET/CT. 62
30688732 2019
163
Development and assessment of 3D-printed individual applicators in gynecological MRI-guided brachytherapy. 62
31139221 2019
164
Primary small cell carcinoma of the vagina: a rare instance of prolonged survival. 62
30852510 2019
165
Primary Clear Cell Carcinoma with no Diethylstilbestrol Exposure; Case Series. 62
30936603 2019
166
Patterns and trends of HPV-related cancers other than cervix in South Africa from 1994-2013. 62
30557819 2019
167
[TNM classification of gynecologic malignancies : What remains to be done beyond 2017?] 62
30707273 2019
168
Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. 62
30674687 2019
169
Melanotic Schwannoma of the Vagina: A Report of a Very Rare Tumor and Review of the Literature. 62
31316847 2019
170
Carcinoma of the lower female genital tract in patients with genitourinary malformations: a clinicopathologic analysis of 36 cases. 62
31281483 2019
171
Severe Vaginal Bleeding in a Case of Renal Cell Carcinoma. 62
31360564 2019
172
Clear cell gynecologic carcinomas: about 5 cases. 62
31934230 2019
173
Vaginal Dysplasia and HIV: An African American and Caribbean American Cohort Study. 62
30693024 2019
174
Importance of Colposcopy Impression in the Early Diagnosis of Posthysterectomy Vaginal Cancer. 62
30418351 2019
175
Laterally extended endopelvic resection with nephrectomy for vaginal cancer. 62
30454878 2019
176
Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. 62
30482913 2019
177
Gabapentin and Cancer Risk: Updated Findings from Kaiser Permanente Northern California. 62
30939265 2019
178
Definitive Radiotherapy in Invasive Vaginal Carcinoma: A Systematic Review. 62
30139838 2019
179
HPV vaccine in the treatment of usual type vulval and vaginal intraepithelial neoplasia: a systematic review. 62
30616555 2019
180
Long-term survival of a patient with malignant transformation of extragonadal endometriosis treated solely with chemotherapy: A case report. 62
30133069 2018
181
A report of human papilloma virus-16 associated vaginal carcinoma after thirty-two years of successful radiation therapy for cervical cancer. 62
30539058 2018
182
Breast and reproductive cancers in the transgender population: a systematic review. 62
29706033 2018
183
Inversely designed, 3D-printed personalized template-guided interstitial brachytherapy for vaginal tumors. 62
30479625 2018
184
Cancer of the vagina. 62
30306589 2018
185
Letter to the Editor Regarding "Perineural Spread Along Spinal and Obturator Nerves in Primary Vaginal Carcinoma: A Case Report". 62
30248810 2018
186
KLK5, a novel potential suppressor of vaginal carcinogenesis. 62
29561728 2018
187
A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer. 62
30044320 2018
188
The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges. 62
29520427 2018
189
Intestinal-type adenocarcinoma of the vagina: clinico-pathologic features of a common tumor with a rare localization. 62
30546144 2018
190
Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. 62
30054103 2018
191
Primary squamous cell carcinoma of the endometrium in a woman of reproductive age: a rare case report. 62
29865971 2018
192
Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina. 62
29929925 2018
193
Role of Intraoperative Ultrasound to Extend the Application of Minimally Invasive Surgery for Treatment of Recurrent Gynecologic Cancer. 62
29325966 2018
194
Perineural Spread Along Spinal and Obturator Nerves in Primary Vaginal Carcinoma: A Case Report. 62
29660549 2018
195
Extraperitoneal Para-Aortic Lymphadenectomy by Robot-Assisted Laparoscopy. 62
29337211 2018
196
Network-based method for mining novel HPV infection related genes using random walk with restart algorithm. 62
29197659 2018
197
Effects of the Affordable Care Act on Young Women With Gynecologic Cancers. 62
29742668 2018
198
Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report. 62
29866134 2018
199
Laparoscopic ovarian transposition prior to pelvic radiation for gynecologic cancer. 62
29915802 2018
200
Image-guided adaptive brachytherapy in primary vaginal cancers: A monocentric experience. 62
29426746 2018
201
The Role of PET Imaging in Gynecologic Radiation Oncology. 62
29482751 2018
202
Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group. 62
29086206 2018
203
Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. 62
29159773 2018
204
[Analysis of the factors associated with the long-term curative effect and prognosis of primary vaginal carcinoma]. 62
29575845 2018
205
Primary non-Hodgkin's lymphoma of the vagina: A case report. 62
29556272 2018
206
Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation. 62
29439180 2018
207
Re-irradiation in Gynaecological Malignancies: A Review. 62
29233573 2018
208
Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas. 62
29274828 2018
209
Clinical outcomes and risk of recurrence among patients with vaginal intraepithelial neoplasia: a comprehensive analysis of 576 cases. 62
29185264 2018
210
Spectrum of Gynecological Malignancies at Jamshoro. 62
29290193 2018
211
When an Unexpected Diagnosis Occurs: a Vaginal Premenopausal Sarcoma. 62
29341035 2018
212
Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina. 62
30285924 2018
213
Epidemiological and economic burden of potentially HPV-related cancers in France. 62
30235216 2018
214
Metastatic Small Cell Carcinoma of the Urinary Bladder That Recurred in the Vagina 6 Years after Radical Cystectomy: A Case Report. 62
30473902 2018
215
Intracavitary vaginal brachytherapy using a custom balloon applicator. 62
28661036 2017
216
Poorly differentiated vaginal adenocarcinoma with aggressive behavior-Pap smear findings. 62
28670843 2017
217
[A Resected Case of the Vaginal Metastasis from Rectal Cancer]. 62
29394659 2017
218
Efficacy of 5% imiquimod for the treatment of Vaginal intraepithelial neoplasia-A systematic review of the literature and a meta-analysis. 62
28985547 2017
219
Molecular characterization, prevalence and clinical relevance of Phodopus sungorus papillomavirus type 1 (PsuPV1) naturally infecting Siberian hamsters (Phodopus sungorus). 62
29022861 2017
220
Vitamin D and VDR in Gynecological Cancers-A Systematic Review. 62
29113037 2017
221
Microbiological diagnosis of human papilloma virus infection. 62
27353835 2017
222
Vaginal tumor-vesical fistula detected by dynamic fluorodeoxyglucose-positron emission tomography/computed tomography: A case report. 62
28779630 2017
223
Robot-assisted gynaecological cancer surgery-complications and prevention. 62
28528932 2017
224
Evaluation of interfractional variation of organs and displacement of catheters during high-dose-rate interstitial brachytherapy for gynecologic malignancies. 62
28993108 2017
225
Schwannoma of the vagina - a common tumor but a rare location: A case report. 62
29181168 2017
226
Pattern of gynaecological malignancies in south western region of Pakistan: An overview of 12 years. 62
29109863 2017
227
[A Case Report of Post-Radiochemotherapy Perineum Abscess Concurrent with Recurrence of Vaginal Cancer for Which Total Pelvic Exenteration Was Performed]. 62
29394768 2017
228
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. 62
28886907 2017
229
Laser Excisional Treatment for Vaginal Intraepithelial Neoplasia to Exclude Invasion: What Is the Risk of Complications? 62
28953124 2017
230
Clinical application of MOSkin dosimeters to rectal wall in vivo dosimetry in gynecological HDR brachytherapy. 62
28499627 2017
231
Effects of neoadjuvant chemotherapy on patients with primary vaginal squamous cell carcinoma. 62
28894577 2017
232
Vaginal Yolk Sac Tumor in an Infant. 62
28969744 2017
233
Endometrial Stromal Sarcoma Arising in Colorectal Endometriosis. 62
27801759 2017
234
Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. 62
28624154 2017
235
Abdominal radical trachelectomy for vaginal cancer - A case report. 62
28664182 2017
236
MR Imaging of Vulvar and Vaginal Cancer. 62
28668156 2017
237
Long-Lasting Increased Risk of Human Papillomavirus-Related Carcinomas and Premalignancies After Cervical Intraepithelial Neoplasia Grade 3: A Population-Based Cohort Study. 62
28541790 2017
238
Two week waits: What are we waiting for? 62
28609712 2017
239
Management of menopausal symptoms in women with gynecologic cancers. 62
28625396 2017
240
Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: Long-term analysis from a clinical viewpoint. 62
28796063 2017
241
Increasing Awareness of Gynecologic Cancer Risks and Symptoms among Asian, Native Hawaiian and Pacific Islander Women in the US-Associated Pacific Island Jurisdictions 62
28843233 2017
242
Vaginal metastasis as the initial presentation of leiomyosarcoma: a case report. 62
28747229 2017
243
Sentinel lymph node mapping with indocyanine green in vaginal cancer. 62
28541627 2017
244
Lichen sclerosus and risk of cancer. 62
28124469 2017
245
Dosimetric comparison of interstitial brachytherapy with multi-channel vaginal cylinder plans in patients with vaginal tumors. 62
28521759 2017
246
Does p53 codon 72 polymorphism have a prognostic value in carcinoma of the vulva and vagina? 62
28144815 2017
247
Colpoplasty by laparoscopic modified Davydov's procedure. 62
28081882 2017
248
Human Papillomavirus and students in Brazil: an assessment of knowledge of a common infection - preliminary report. 62
27170346 2017
249
Paget's disease of the vulva: A review of 89 cases. 62
28124023 2017
250
Therapy-related acute myeloid leukemia in a patient of vaginal carcinoma post-chemoradiation with latency of 15 months: Case report. 62
27922282 2017
251
Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. 62
28400857 2017
252
Non-diethylstilbestrol exposed vaginal adenocarcinoma in young patients associated with unilateral renal agenesis: two case reports and literature review. 62
29767889 2017
253
Definitive Radiotherapy for Primary Squamous Cell Carcinoma of the Vagina: Are High-Dose External Beam Radiotherapy and High-Dose-Rate Brachytherapy Boost the Best Treatment? Experience of Two Italian Institutes. 62
29065399 2017
254
Malignant Transformation of Vaginal Endometriosis - A Review of Literature. 62
27618565 2017
255
Risk factors to develop multicentric lesions of the lower genital tract. 62
29767857 2017
256
Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma. 62
28841699 2017
257
Gel Sonovaginography: A New Way of Evaluating a Variety of Local Vaginal and Cervical Disorders. 62
27821656 2016
258
Vaginal delivery of carboplatin-loaded thermosensitive hydrogel to prevent local cervical cancer recurrence in mice. 62
27340764 2016
259
Prognostic Factors in Primary Vaginal Cancer: A Single Institute Experience and Review of Literature. 62
27486283 2016
260
Characterizing gradient echo signal decays in gynecologic cancers at 3T using a Gaussian augmentation of the monoexponential (GAME) model. 62
26971387 2016
261
Bladder and vaginal transitional cell carcinoma: A case report. 62
27602160 2016
262
Positron Emission Tomography/Computed Tomography for Gynecologic Malignancies. 62
27640609 2016
263
Outcomes with image-based interstitial brachytherapy for vaginal cancer. 62
27321150 2016
264
Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. 62
27536721 2016
265
Long-Term Risk for Noncervical Anogenital Cancer in Women with Previously Diagnosed High-Grade Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study. 62
27358257 2016
266
Abnormal Vaginal Pap Test Results After Hysterectomy in Human Immunodeficiency Virus-Infected Women. 62
27275815 2016
267
Breast metastasis from vaginal cancer. 62
27444140 2016
268
Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience. 62
27327154 2016
269
Brachytherapy improves survival in primary vaginal cancer. 62
27036631 2016
270
Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. 62
26994695 2016
271
Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. 62
26914159 2016
272
Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. 62
26970567 2016
273
A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. 62
26915529 2016
274
Abnormal Vaginal Pap Test After Hysterectomy in Human Immunodeficiency Virus-Infected Women. 62
28469285 2016
275
Vulval and vaginal cancer in pregnancy. 62
26526939 2016
276
Vulvar and Vaginal Cancer, Vulvar Intraepithelial Neoplasia 3 and Vaginal Intraepithelial Neoplasia 3: Experience of a Referral Institute. 62
27430086 2016
277
A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results. 62
26901279 2016
278
Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study. 62
27069175 2016
279
Radical Hysterectomy and Total Abdominal Vaginectomy for Primary Vaginal Cancer. 62
26825828 2016
280
High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). 62
27010135 2016
281
The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. 62
26790773 2016
282
Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). 62
26768782 2016
283
An isolated vaginal metastasis from rectal cancer. 62
26793313 2016
284
A rare case of giant vaginal fibromyoma. 62
26989649 2016
285
Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia. 62
26232937 2016
286
[The Vaginal Metastasis of Ureteral Carcinoma after Left Nephroureterectomy: A Case Report]. 62
27018410 2016
287
Detection of Human Papillomavirus Infection in Patients with Vaginal Intraepithelial Neoplasia. 62
27907089 2016
288
Computed tomography-planned interstitial brachytherapy for locally advanced gynecologic cancer: Outcomes and dosimetric predictors of urinary toxicity. 62
26614237 2016
289
Detection and Type-Distribution of Human Papillomavirus in Vulva and Vaginal Abnormal Cytology Lesions and Cancer Tissues from Thai Women. 62
27039737 2016
290
Retrospective evaluation of clinical and pathological features, as well as diagnostic and treatment protocols of primary vaginal malignancy. 62
27629126 2016
291
Proton Therapy for Vaginal Reirradiation. 62
28989947 2016
292
Vaginal Intraepithelial Neoplasia: Histopathological Upgrading of Lesions and Evidence of Occult Vaginal Cancer. 62
26461231 2016
293
Cancer Care Delivery and Women's Health: The Role of Patient Navigation. 62
26858934 2016
294
Outcomes of Definitive Radiation Therapy for Primary Vaginal Carcinoma. 62
24136141 2015
295
Sarcoid-like reaction mimicking vaginal cancer recurrence. 62
26420533 2015
296
Primary Vaginal Non-Hodgkin's Lymphoma: Report of a Rare Clinical Entity. 62
26918105 2015
297
Pilot study assessing (18)F-fluorothymidine PET/CT in cervical and vaginal cancers before and after external beam radiation. 62
26793770 2015
298
[Treatment results for different categories of vaginal intraepithelial neoplasia with electrocoagulation, 5-fluorouracil and combined treatment]. 62
26859921 2015
299
Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art. 62
26271829 2015
300
Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. 62
26121913 2015
301
Staging for vaginal cancer. 62
25847318 2015
302
Brachytherapy for malignancies of the vagina in the 3D era. 62
26622234 2015
303
Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. 62
25966291 2015
304
Vaginal metastasis presenting as postmenopausal bleeding. 62
26311914 2015
305
RADICAL HYSTERECTOMY IN SURGICAL TREATMENT OF INVASIVE CERVICAL CANCER AT THE DEPARTMENT OF GYNECOLOGY AND OBSTETRICS IN NOVI SAD IN THE PERIOD 1993-2013. 62
26591634 2015
306
The use of cisplatin-loaded mucoadhesive nanofibers for local chemotherapy of cervical cancers in mice. 62
25843238 2015
307
Vulvar and vaginal reconstruction using the "angel wing" perforator-based island flap. 62
25838163 2015
308
Vaginal carcinoma in a young woman who underwent fertility-sparing treatment involving chemotherapy and conservative surgery. 62
25512111 2015
309
MRI findings in primary vaginal melanoma-a report of four cases. 62
25560672 2015
310
Ovarian torsion after laparoscopic ovarian transposition in patients with gynecologic cancer: a report of two cases. 62
25772021 2015
311
Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice. 62
25735256 2015
312
[Magnetic resonance imaging in the diagnosis of secondary vaginal tumor involvement]. 62
26302621 2015
313
PROGNOSTIC SIGNIFICANCE OF TUMOR SIZE IN SQUAMOUS CELL CARCINOMA OF THE VULVA: IGCS-0107 Vulvar and Vaginal Cancer. 62
25955951 2015
314
Successful pregnancy after uterus-sparing chemoradiation therapy for vaginal cancer. 62
25432539 2015
315
LASER VAPORIZATION IN VULVAR INTRAEPITHELIAL NEOPLASIA (VIN), VAGINAL INTRAEPITHELIAL NEOPLASIA (VAIN) AND CONDYLOMATA ACUMINATA: IGCS-0093 Vulvar and Vaginal Cancer. 62
25955950 2015
316
Is there a subset of patients with recurrent cancer in the vagina who are not candidates for interstitial brachytherapy that can be treated with multichannel vaginal brachytherapy using graphic optimization? 62
26034494 2015
317
Time to surgery and the risk of cancer progression in patients with gynaecologic cancers of the lower genital tract. 62
26001687 2015
318
Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rate. 62
25614068 2015
319
A unique approach to high-dose-rate vaginal mold brachytherapy of gynecologic malignancies. 62
25466360 2015
320
Clinical characteristics of non-squamous cell carcinoma of the vagina. 62
25594143 2015
321
Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer. 62
25456026 2015
322
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. 62
27231570 2015
323
Matched-Case Comparisons in a Single Institution to Determine Critical Points for Inexperienced Surgeons' Successful Performances of Laparoscopic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Stage IA2-IIA Cervical Cancer. 62
26110866 2015
324
Management of Vaginal Cancer. 62
26411952 2015
325
Primary Vulvo-Vaginal Cancers: Trends in Incidence and Mortality in Poland (1999-2012). 62
26065364 2015
326
First two cases of primary carcinoma of the vagina successfully treated with concurrent weekly carboplatin plus paclitaxel, external beam radiotherapy and high-dose-rate interstitial brachytherapy: a case report and published work review. 62
25227150 2015
327
Patterns of care and brachytherapy boost utilization for vaginal cancer in the United States. 62
25413431 2015
328
Spindle-cell epithelioma of the vagina diagnosed during pregnancy--a case report. 62
26050367 2015
329
CO2 laser vaporization for the treatment of vaginal intraepithelial neoplasia: effectiveness and predictive factors for recurrence. 62
26390687 2015
330
Gestational choriocarcinoma after term pregnancy: a case report. 62
25826515 2015
331
Congenital urethral polyps in girls: as a differential diagnosis of interlabial masses. 62
25256883 2014
332
Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. 62
25281493 2014
333
Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. 62
25155250 2014
334
Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer. 62
25254565 2014
335
Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1. 62
25319982 2014
336
Laser-skinning colpectomy for extended vaginal intraepithelial neoplasia and microinvasive cancer. 62
25159485 2014
337
Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method. 62
25248115 2014
338
Is there an association between polypropylene midurethral slings and malignancy? 62
25260443 2014
339
Comparison of laparoscopic peritoneal vaginoplasty and sigmoid colon vaginoplasty performed during radical surgery for primary vaginal carcinoma. 62
25266567 2014
340
Histo-pathological Features of Genital Tract Malignancies as Seen in a Tertiary Health Center in North-Western Nigeria: A 10-year Review. 62
25364591 2014
341
Vaginal cancer in a patient with complicated prolapse history: a case report. 62
25181382 2014
342
High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction of DNA damage response, an activity mediated by E7's inactivation of pocket proteins. 62
24013229 2014
343
What do women with gynecologic cancer know about HPV and their individual disease? A pilot study. 62
24885465 2014
344
Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy. 62
24080298 2014
345
Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. 62
24785610 2014
346
Vaginal intraepithelial neoplasia (VaIN 2/3): comparing clinical outcomes of treatment with intravaginal estrogen. 62
24189311 2014
347
Erlotinib in a patient with vaginal carcinoma and pulmonary metastasis: A case report. 62
24527088 2014
348
[Clinical usefulness of diagnostic methods for human papilloma virus dependent lesions]. 62
24720112 2014
349
Viral load, integration and methylation of E2BS3 and 4 in human papilloma virus (HPV) 16-positive vaginal and vulvar carcinomas. 62
25393237 2014
350
Pelvic exenteration: impact of age on surgical and oncologic outcomes. 62
24262877 2014
351
Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. 62
24505474 2014
352
Uterine prolapse complicated by vaginal cancer: a case report and literature review. 62
24481208 2014
353
HDR brachytherapy for the reirradiation of cervical and vaginal cancer: analysis of efficacy and dosage delivered to organs at risk. 62
24161366 2014
354
Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. 62
24423603 2014
355
Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. 62
24362721 2014
356
A case of vaginal cancer with uterine prolapse. 62
25371880 2013
357
A clinicopathologic study of vaginal intraepithelial neoplasia. 62
24201676 2013
358
Acr appropriateness Criteria management of vaginal cancer. 62
24575547 2013
359
Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival. 62
24396823 2013
360
Is there a place for sentinel technique in treatment of vaginal cancer?: feasibility, clinical experience, and results. 62
24177255 2013
361
Vaginal cancer: the experience from 2 large academic centers during a 15-year period. 62
23609592 2013
362
[Management of vaginal carcinoma in patients over 70 years old: advantage of a radiotherapy-brachytherapy association]. 62
23969306 2013
363
[Clinical and endocrinological findings of bitches with ovarian cyst syndrome]. 62
24091229 2013
364
Primary vaginal carcinoma of lower one-third of posterior vagina associated with third-degree prolapse: a rare case. 62
24431677 2013
365
Role of vault cytology in follow-up of hysterectomized women: results and inferences from a low resource setting. 62
23288466 2013
366
Radiation therapy for primary vaginal carcinoma. 62
23559599 2013
367
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. 62
23345000 2013
368
Radical hysterectomy and vaginectomy with sigmoid vaginoplasty for stage I vaginal carcinoma. 62
23683871 2013
369
[A rare vaginal tumor]. 62
23954127 2013
370
Spindle cell epithelioma: a rare vaginal tumor -a clinico pathologic report. 62
24086899 2013
371
An unusual presentation of a urethral diverticulum as a vaginal wall mass: a case report. 62
23815779 2013
372
Post-hysterectomy vaginal cuff cancer secondary to HPV infection and CIN: A case report. 62
24353691 2013
373
Vulvar and vaginal HPV disease. 62
23732036 2013
374
Laparoscopic upper vaginectomy for post-hysterectomy high risk vaginal intraepithelial neoplasia and superficially invasive vaginal carcinoma. 62
23725440 2013
375
The use of laparostomy in patients with gynecologic cancer: first report from a UK cancer center. 62
23571659 2013
376
Adjuvant and definitive radiation therapy for primary carcinoma of the vagina using brachytherapy and external beam radiation therapy. 62
23878551 2013
377
Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? 62
23212765 2013
378
Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma. 62
23402906 2013
379
Radiotherapy for carcinoma of the vagina. Immunocytochemical and cytofluorometric analysis of prognostic factors. 62
23553046 2013
380
What is hiding behind the pessary? 62
22790489 2013
381
Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer. 62
23453679 2013
382
HLA-G 3'UTR polymorphisms in high grade and invasive cervico-vaginal cancer. 62
23228396 2013
383
[The first vaccine against cancer: the human papillomavirus vaccine]. 62
23587540 2013
384
Definitive radiation therapy for invasive carcinoma of the vagina: impact of high-dose rate intracavitary brachytherapy. 62
22310898 2013
385
Primary neuroendocrine carcinoma of the vagina with coexistent atypical vaginal adenosis: a rare entity. 62
23771390 2013
386
Human papillomavirus: what every provider should know. 62
23021131 2013
387
Radiation therapy complications in patients with primary invasive vaginal carcinoma. 62
23700848 2013
388
Embryonal rhabdomyosarcoma (botryoid type) of the uterine corpus and cervix in adult women: report of a case series and review of the literature. 62
23348207 2013
389
[Total pelvic exenteration in vaginal cancer--case report]. 62
23668062 2013
390
Urethral prolapse misdiagnosed as vaginal tumor in an elderly woman. 62
23526281 2013
391
Effectiveness of radiotherapy in patients with primary invasive vaginal carcinoma. 62
24475578 2013
392
Sucralfate or placebo following argon plasma coagulation for chronic radiation proctitis: a randomized double blind trial. 62
23006660 2013
393
Concurrent chemoradiation for vaginal cancer. 62
23762284 2013
394
Gynecological malignancies in Aminu Kano Teaching Hospital Kano: a 3 year review. 62
23377473 2013
395
Epidemiology of HPV-related female cancers in the Umbria region of Italy: pre-vaccination period. 62
24020136 2013
396
Is radical hysterectomy necessary in early cervical cancer? 62
24051740 2013
397
A case of small cell carcinoma of the vagina. 62
24416492 2013
398
Prognostic factors in patients with primary invasive vaginal carcinoma. 62
23488292 2012
399
Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia. 62
23276555 2012
400
Cutaneous metastasis from primary adenocarcinoma of the vagina: a case report. 62
22563980 2012
401
[Our experiences of anal squamous cell carcinoma treated by chemoradiotherapy]. 62
23268016 2012
402
Opportunities for 2-[(18)F] fluoro-2-deoxy-D-glucose PET/CT in cervical-vaginal neuroendocrine carcinoma: case series and literature review. 62
23118575 2012
403
Quality of life valuations of HPV-associated cancer health states by the general population. 62
22645393 2012
404
[Primary leiomyosarcoma of the vagina: a clinical analysis of 9 cases]. 62
23302732 2012
405
Laparoscopic nerve-sparing radical vaginectomy in patients with vaginal carcinoma: surgical technique and operative outcomes. 62
22841659 2012
406
Diagnostic challenges of hemihematocolpos and dysmenorrhea in adolescents: obstructed hemivagina, didelphys or bicornuate uterus and renal aplasia is a rare female genital malformation. 62
22669164 2012
407
Cervicovaginal human papillomavirus (HPV)-infection before and after hysterectomy: evidence of different tissue tropism for oncogenic and nononcogenic HPV types in a cohort of HIV-positive and HIV-negative women. 62
22120980 2012
408
Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies. 62
23997512 2012
409
Estimation of the optimal brachytherapy utilisation rate in the treatment of vaginal cancer and comparison with patterns of care. 62
22883660 2012
410
Vaginal vault carcinoma as second primary in a treated case of ovarian cancer. 62
23372331 2012
411
Acrometastasis to hand in vaginal carcinoma: a rare entity. 62
23174728 2012
412
SU-E-T-148: An Optimizing Study of a New Multi Channel Virginal Cylinder Applicator in Brachytherapy. 62
28517849 2012
413
SU-E-T-306: An Optimized Dosimetry Study Comparing a Multichannel Cylinder versus Single Channel Cylinder in the Treatment of the Vaginal Cuff or Vagina with High Dose Rate Brachytherapy. 62
28517268 2012
414
Vulvar and vaginal cancer. 62
22640712 2012
415
[Vulvar cancer and vaginal cancer: precursor lesions and diagnoses]. 62
23156332 2012
416
[Treatment of vulvar and vaginal cancer]. 62
23156333 2012
417
Three-dimensional image-based high-dose-rate interstitial brachytherapy for vaginal cancer. 62
21665553 2012
418
[Malignant melanoma of the vagina: pejorative location]. 62
22336523 2012
419
Prenatal exposure to diethylstilbestrol and long-term impact on the breast and reproductive tract in humans and mice. 62
25101917 2012
420
Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. 62
21868174 2012
421
Carcinoma of vagina in utero-vaginal prolapse: a rare presentation. 62
23478736 2012
422
Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans. 62
22928063 2012
423
Preliminary short-term outcomes of a modified double-T ileal continent cutaneous urinary diversion using Yang-Monti tube implantation through serosa-lined extramural tunnel: the PGIMER pouch. 62
22469584 2012
424
High expression of TGF-β1 in the vaginal incisional margin predicts poor prognosis in patients with stage Ib-IIa cervical squamous cell carcinoma. 62
21773949 2012
425
Risk factors for the development of vaginal intraepithelial neoplasia. 62
22613591 2012
426
Aggressive clinical course of primary invasive vaginal carcinoma associated with type 61 HPV: a case report. 62
22678006 2012
427
Vaginal cancer. 62
21571543 2012
428
Definitive radiotherapy for treatment of primary vaginal cancer: effectiveness and prognostic factors. 62
22367326 2012
429
Vaginal cancer following etoposide-containing chemotherapy for metastatic gestational trophoblastic tumour. 62
22296447 2012
430
Clinicopathological study of 112 cases of benign, pre-invasive and invasive lesions of the vagina: a 15-year review. 62
23185788 2012
431
Malignant lymphoma of the vagina successfully treated with rituximab, adryamicin, cyclophosphamide, vincristine sulfate, and prednisolone. 62
22611969 2012
432
American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. 62
22265440 2012
433
[A woman with a vaginal tumor]. 62
22759706 2012
434
Interstitial brachytherapy using virtual planning and Doppler transrectal ultrasonography guidance for internal iliac lymph node metastasis. 62
22240939 2012
435
Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer. 62
22943045 2012
436
Psychological consequences of DES exposure in utero. 62
22066313 2011
437
Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2. 62
22037656 2011
438
Cervical and vaginal cancer in a woman with chronic graft-versus-host disease. 62
21669422 2011
439
Underuse of ovarian transposition in reproductive-aged cancer patients treated by primary or adjuvant pelvic irradiation. 62
21450024 2011
440
The prognostic role of human papillomavirus in patients with vaginal cancer. 62
21666483 2011
441
Epidemiology of vulvar and vaginal cancer in Germany. 62
21340687 2011
442
Disparities in treatment and survival between African American and White women with vaginal cancer. 62
21497383 2011
443
Non-Hodgkin's lymphoma of the vaginal wall in a hemodialysis patient with hepatocellular carcinoma. 62
21699006 2011
444
Metabolic syndrome and rare gynecological cancers in the metabolic syndrome and cancer project (Me-Can). 62
20966183 2011
445
A novel treatment for haemorrhagic radiation proctitis using colonic irrigation and oral antibiotic administration. 62
21114751 2011
446
Pattern of gynaecological cancers in University of Nigeria Teaching Hospital, Enugu, south eastern Nigeria. 62
21970241 2011
447
Why the Pap test? Awareness and use of the Pap test among women in the United States. 62
21443450 2011
448
[The accuracy of FDG-PET/CT in early-stage cervical and vaginal cancers]. 62
21429783 2011
449
Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. 62
21343768 2011
450
[Risk factors associated with prognosis in patients with radiation proctitis]. 62
21442481 2011
451
Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis. 62
21270620 2011
452
Fibula metastasis as the presenting feature of vaginal cancer. 62
21446341 2011
453
Vertical rectus abdominis myocutaneous flap for vaginal reconstruction after radical pelvic surgery for Stage II vaginal carcinoma. 62
21614921 2011
454
Primary small cell neuroendocrine carcinoma of vagina: a rare case report. 62
21977334 2011
455
Attitudes toward HPV Vaccination among Women Aged 27 to 45. 62
21776401 2011
456
Robotically-assisted laparoscopic radical parametrectomy and radical vaginectomy. 62
22335034 2011
457
Non-muscle invasive bladder cancer with concomitant vaginal urothelial carcinoma: a case report and review of the literature. 62
20544250 2010
458
Primary large cell neuroendocrine carcinoma of the vagina: cytomorphology of previously unreported case. 62
20222107 2010
459
Neoadjuvant chemotherapy followed by radical surgery and reconstruction of the vagina in a patient with stage II primary vaginal squamous carcinoma. 62
20731765 2010
460
Vaginal Lymphoma with Immune Thrombocytopenic Purpura: An Unusual Case Report. 62
21113350 2010
461
Vaginal carcinoma in a female-to-male transsexual. 62
20102482 2010
462
Genital tract malignancies in postmenopausal women. 62
22338412 2010
463
Advances in vulvar and vaginal cancer treatment. 62
20471671 2010
464
Vaginal and (uncommon) cervical cancers in the Netherlands, 1989-2003. 62
20686385 2010
465
Primary carcinoma of the vagina. 62
20658716 2010
466
[Cause of recurrent metrorrhagia: report of a rare vaginal tumor]. 62
20389272 2010
467
Use of combined radiation and hyperthermia for gynecological cancer. 62
20019611 2010
468
Diagnostic protein marker patterns in squamous cervical cancer. 62
21137014 2010
469
[Ten-year experience with use of Tantum Rosa drug for prevention and therapy of radiation-related rectitis and vaginitis in uterine and vaginal cancer]. 62
21395131 2010
470
Laparoscopic vaginal reconstruction using an ileal segment. 62
19665118 2009
471
Vulvar and vaginal cancers and dysplasia in France--an analysis of the hospital medical information system (PMSI) database. 62
19735968 2009
472
The utility of the human papillomavirus DNA load for the diagnosis and prediction of persistent vaginal intraepithelial neoplasia. 62
20041100 2009
473
Vesicovaginal fistula caused by a vaginal foreign body in a 72-year-old woman: case report and literature review. 62
19834759 2009
474
A rare case of invasive vaginal carcinoma associated with vaginal prolapse. 62
19263061 2009
475
Update of HPV-associated female genital cancers in the United States, 1999-2004. 62
19951205 2009
476
The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. 62
19453788 2009
477
Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. 62
19501390 2009
478
Role of PET in gynecologic malignancy. 62
19553814 2009
479
[A case of primary urethral adenocarcinoma accompanied by vaginal wall infiltration in which the CA19-9 level was very high]. 62
19764540 2009
480
Successful Treatment of Primary Vaginal Papillary Serous Adenocarcinoma Using Chemoradiation Followed by Brachytherapy. 62
20740170 2009
481
Factors affecting risk of mortality in women with vaginal cancer. 62
19384118 2009
482
Indiana University experience in the management of vaginal cancer. 62
19509572 2009
483
The HPV vaccines--which to prefer? 62
19386141 2009
484
Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. 62
19305339 2009
485
Differential tissue-specific protein markers of vaginal carcinoma. 62
19367286 2009
486
Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. 62
19195765 2009
487
Long-term results of radiotherapy in primary carcinoma of the vagina. 62
19330296 2009
488
Verification of computerized treatment planning for HDR 192Ir brachytherapy for gynaecological cancer. 62
19260579 2009
489
First laparoscopic repair of neovaginal prolapse following ileocecal reconstruction after resection of vaginal carcinoma. 62
18976150 2009
490
[Does hormonal contraception increase the risk for tumors?]. 62
19180433 2009
491
PET and PET-CT imaging of gynecological malignancies: present role and future promise. 62
19105709 2009
492
A two eterochronous primary gynaecological malignancies of different origin. 62
20120445 2009
493
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. 62
19127256 2009
494
Primary invasive carcinoma of vagina with third degree uterovaginal prolapse: a case report and review of literature. 62
18936946 2009
495
Neoadjuvant chemotherapy followed by radical surgery in patients affected by vaginal carcinoma. 62
18708243 2008
496
Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. 62
18722657 2008
497
Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. 62
18980291 2008
498
Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan. 62
18757080 2008
499
A young woman with distant recurrent metastatic primary vaginal carcinoma salvaged with radical radiotherapy. 62
18935926 2008
500
Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. 62
18704634 2008
501
Gynecological cancer incidence in a hospital population in Saudi Arabia: the effect of foreign immigration over two decades. 62
18937706 2008
502
Potential of dose optimisation in MRI-based PDR brachytherapy of cervix carcinoma. 62
18037524 2008
503
Hyperthermia to improve results in vaginal cancer. 62
18295920 2008
504
A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. 62
18628412 2008
505
Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice. 62
18405946 2008
506
Re: a new technique of vaginal reconstruction with the deep inferior epigastric perforator flap: a preliminary report. 62
18441535 2008
507
Laparoscopic radical hysterectomy with vaginectomy and reconstruction of vagina in patients with stage I of primary vaginal carcinoma. 62
18237770 2008
508
Spectrum of HIV/AIDS related cancers in India. 62
17992576 2008
509
Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. 62
17680280 2008
510
Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. 62
18190952 2008
511
High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina. 62
18271958 2008
512
[Surgical treatment of advanced radioresistant vaginal carcinoma. Case report]. 62
18938286 2008
513
Human papillomavirus-related gynecologic neoplasms: screening and prevention. 62
19173019 2008
514
Glassy cell carcinoma arising in the vagina. 62
18720032 2008
515
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). 62
17910981 2007
516
The spectrum and clinical sequelae of human papillomavirus infection. 62
18499914 2007
517
Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. 62
17959735 2007
518
Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. 62
17512130 2007
519
Symptomatic vaginal bleeding in a postmenopausal woman: a case report of pancreatic adenocarcinoma metastasizing exclusively to the vagina. 62
17980174 2007
520
A rare case of primary invasive carcinoma of vagina associated with irreducible third degree uterovaginal prolapse. 62
17628814 2007
521
Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases. 62
17895749 2007
522
Secondary vaginal involvement following radical surgical treatment for a stage I ovarian adenocarcinoma arising in mature cystic teratoma. 62
18041444 2007
523
Carbon ion radiotherapy for vaginal malignant melanoma: a case report. 62
17451456 2007
524
20-year retrospective review of medium dose rate intracavitary brachytherapy in VAIN3. 62
17481703 2007
525
A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. 62
17477959 2007
526
Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: a cohort study. 62
16774806 2007
527
Stage II squamous cell carcinoma of the vagina in a patient with Bloom syndrome: a case report. 62
17694984 2007
528
Vaginal carcinoma in a completely prolapsed uterus. A case report. 62
17123094 2007
529
Magnetic resonance imaging of primary vaginal carcinoma. 62
17467392 2007
530
Exposure of juvenile female mice to isoflavone causes lowered expression of estrogen-related receptor gamma gene in vagina. 62
17478075 2007
531
[Acute urinary retention in primary vaginal carcinoma: therapeutic approach]. 62
17687867 2007
532
A leg ulcer as manifestation of metastatic squamous cell vaginal carcinoma. 62
17447983 2007
533
Prediction of persistent vaginal intraepithelial neoplasia in previously hysterectomized women by high-risk HPV DNA detection. 62
17070990 2007
534
Light chain deposition disease involving the airways: diagnosis by fibreoptic bronchoscopy. 62
17470625 2007
535
Positron emission tomography imaging for gynecologic malignancy. 62
17218850 2007
536
Non-Hodgkin's lymphoma mimicking gynecological malignancies of the vagina and cervix: a report of four cases. 62
17291267 2007
537
Extended abdominoperineal resection in women: the Barbadian experience. 62
17214895 2007
538
Salivary duct carcinoma presenting with vaginal metastasis: case report. 62
17966226 2007
539
Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. 62
17081187 2006
540
Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. 62
17138767 2006
541
[A look beyond urology: vaginal cancer]. 62
16902789 2006
542
[Prognostic factors of vaginal cancer]. 62
17197742 2006
543
How innocent is the vaginal pessary? Two cases of vaginal cancer associated with pessary use. 62
17130056 2006
544
Audit of preoperative and early complications of laparoscopic lymph node dissection in 1000 gynecologic cancer patients. 62
16677594 2006
545
CHAPTER 8 HPV vaccines. 62
29644642 2006
546
A3. Vaginal intraepithelial neoplasia (VAIN). 62
29644629 2006
547
High-dose-rate interstitial brachytherapy for gynecologic malignancies. 62
17118313 2006
548
Conservative treatment of reproductive and sexual function in young woman with squamous carcinoma of the vagina. 62
16595145 2006
549
Age at natural menopause in women exposed to diethylstilbestrol in utero. 62
16887893 2006
550
Routine vaginal Pap test is not useful in women status-post hysterectomy for benign disease. 62
16900480 2006
551
Gynecological cancers in developing countries: the challenge of chemotherapy in low-resources setting. 62
16884356 2006
552
Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin. 62
16406065 2006
553
[Deep inferior epigastric perforator flap for vaginal reconstruction]. 62
16752843 2006
554
Laparoscopic management of vaginal clear cell adenocarcinoma arising in pelvic endometriosis: case report and literature review. 62
16698533 2006
555
Radiation therapy for gynecologic malignancies. 62
16730298 2006
556
Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. 62
16284947 2006
557
Clomiphene and hypospadias on a detailed level: signal or chance? 62
16586447 2006
558
The role of interstitial brachytherapy in the treatment of vaginal and vulvar malignancies. 62
16520908 2006
559
Invasive squamous cell carcinoma of the vagina in the setting of true hermaphroditism. 62
16171851 2006
560
Vaginal cancer in a patient treated for cervical intraepithelial neoplasia (CIN 3): case report. 62
17290605 2006
561
Management of a case of primary vaginal cancer with irreducible massive uterine prolapse--a case report. 62
17139994 2006
562
[Vagina cancer in a young woman exposed to diethylstilbestrol: case report and literature review]. 62
16583845 2005
563
Radiotherapy for the treatment of primary vaginal cancer. 62
16260055 2005
564
Radiofrequency ablation for the treatment of hemorrhagic vaginal cancer. 62
16319167 2005
565
Formation of functional neovagina with vertical rectus abdominis musculocutaneous (VRAM) flap after total pelvic exenteration. 62
16258296 2005
566
Perivascular epithelioid tumor of urinary bladder and vagina. 62
16198955 2005
567
Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. 62
16054678 2005
568
Stage I squamous cell carcinoma of vagina complicating pregnancy: successful conservative treatment. 62
15987657 2005
569
Pelvic irradiation-induced eosinophilia is correlated to prognosis of cervical cancer patients and transient elevation of serum interleukin 5 level. 62
16342902 2005
570
FDG-PET evaluation of vaginal carcinoma. 62
15936553 2005
571
Vaginal metastasis of lung cancer: a case report. 62
16033075 2005
572
Recurrence of vaginal implantation of transitional cell carcinoma of the urinary tract. 62
15863178 2005
573
Brachytherapy management of the retroverted uterus using ultrasound-guided implant applicator placement. 62
15737903 2005
574
[Initial experience in exenteration interventions in the pelvis]. 62
15633419 2004
575
Laparoscopic port-site metastases in patients with gynecological malignancies. 62